#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Repetition of verbal fluency task attenuates the hemodynamic activation in the left prefrontal cortex: Enhancing the clinical usefulness of near-infrared spectroscopy
#Text=In applications of near-infrared spectroscopy (NIRS) in clinical psychiatry settings in Japan, a phonemic verbal fluency test (VFT) that includes “switching” (the ability to shift efficiently to a new word subcategory) to assess phonemic fluency is employed to capture disease-specific hemodynamic changes in the prefrontal cortex (PFC).
1-1	0-10	Repetition	_	
1-2	11-13	of	_	
1-3	14-20	verbal	_	
1-4	21-28	fluency	_	
1-5	29-33	task	_	
1-6	34-44	attenuates	_	
1-7	45-48	the	_	
1-8	49-60	hemodynamic	_	
1-9	61-71	activation	_	
1-10	72-74	in	_	
1-11	75-78	the	_	
1-12	79-83	left	_	
1-13	84-94	prefrontal	_	
1-14	95-101	cortex	_	
1-15	101-102	:	_	
1-16	103-112	Enhancing	_	
1-17	113-116	the	_	
1-18	117-125	clinical	_	
1-19	126-136	usefulness	_	
1-20	137-139	of	_	
1-21	140-153	near-infrared	_	
1-22	154-166	spectroscopy	_	
1-23	167-169	In	_	
1-24	170-182	applications	_	
1-25	183-185	of	_	
1-26	186-199	near-infrared	_	
1-27	200-212	spectroscopy	_	
1-28	213-214	(	_	
1-29	214-218	NIRS	_	
1-30	218-219	)	_	
1-31	220-222	in	_	
1-32	223-231	clinical	_	
1-33	232-242	psychiatry	_	
1-34	243-251	settings	_	
1-35	252-254	in	_	
1-36	255-260	Japan	_	
1-37	260-261	,	_	
1-38	262-263	a	_	
1-39	264-272	phonemic	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-40	273-279	verbal	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-41	280-287	fluency	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-42	288-292	test	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-43	293-294	(	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-44	294-297	VFT	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-45	297-298	)	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask[1]	
1-46	299-303	that	_	
1-47	304-312	includes	_	
1-48	313-314	“	_	
1-49	314-323	switching	_	
1-50	323-324	”	_	
1-51	325-326	(	_	
1-52	326-329	the	_	
1-53	330-337	ability	_	
1-54	338-340	to	_	
1-55	341-346	shift	_	
1-56	347-358	efficiently	_	
1-57	359-361	to	_	
1-58	362-363	a	_	
1-59	364-367	new	_	
1-60	368-372	word	_	
1-61	373-384	subcategory	_	
1-62	384-385	)	_	
1-63	386-388	to	_	
1-64	389-395	assess	_	
1-65	396-404	phonemic	_	
1-66	405-412	fluency	_	
1-67	413-415	is	_	
1-68	416-424	employed	_	
1-69	425-427	to	_	
1-70	428-435	capture	_	
1-71	436-452	disease-specific	_	
1-72	453-464	hemodynamic	_	
1-73	465-472	changes	_	
1-74	473-475	in	_	
1-75	476-479	the	_	
1-76	480-490	prefrontal	_	
1-77	491-497	cortex	_	
1-78	498-499	(	_	
1-79	499-502	PFC	_	
1-80	502-503	)	_	
1-81	503-504	.	_	

#Text=In this study, to extend the specific features of this test, the VFT was repeated to examine an activation change in NIRS measurements in 20 healthy males.
2-1	505-507	In	_	
2-2	508-512	this	_	
2-3	513-518	study	_	
2-4	518-519	,	_	
2-5	520-522	to	_	
2-6	523-529	extend	_	
2-7	530-533	the	_	
2-8	534-542	specific	_	
2-9	543-551	features	_	
2-10	552-554	of	_	
2-11	555-559	this	_	
2-12	560-564	test	_	
2-13	564-565	,	_	
2-14	566-569	the	_	
2-15	570-573	VFT	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask	
2-16	574-577	was	_	
2-17	578-586	repeated	_	
2-18	587-589	to	_	
2-19	590-597	examine	_	
2-20	598-600	an	_	
2-21	601-611	activation	_	
2-22	612-618	change	_	
2-23	619-621	in	_	
2-24	622-626	NIRS	_	
2-25	627-639	measurements	_	
2-26	640-642	in	_	
2-27	643-645	20	_	
2-28	646-653	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-29	654-659	males	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
2-30	659-660	.	_	

#Text=Without task performance change, the hemodynamic activation induced by the VFT was significantly attenuated in the left PFC through repetition of the task.
3-1	661-668	Without	_	
3-2	669-673	task	_	
3-3	674-685	performance	_	
3-4	686-692	change	_	
3-5	692-693	,	_	
3-6	694-697	the	_	
3-7	698-709	hemodynamic	_	
3-8	710-720	activation	_	
3-9	721-728	induced	_	
3-10	729-731	by	_	
3-11	732-735	the	_	
3-12	736-739	VFT	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask	
3-13	740-743	was	_	
3-14	744-757	significantly	_	
3-15	758-768	attenuated	_	
3-16	769-771	in	_	
3-17	772-775	the	_	
3-18	776-780	left	_	
3-19	781-784	PFC	_	
3-20	785-792	through	_	
3-21	793-803	repetition	_	
3-22	804-806	of	_	
3-23	807-810	the	_	
3-24	811-815	task	_	
3-25	815-816	.	_	

#Text=These findings suggest that the left PFC is involved in processing of the VFT.
4-1	817-822	These	_	
4-2	823-831	findings	_	
4-3	832-839	suggest	_	
4-4	840-844	that	_	
4-5	845-848	the	_	
4-6	849-853	left	_	
4-7	854-857	PFC	_	
4-8	858-860	is	_	
4-9	861-869	involved	_	
4-10	870-872	in	_	
4-11	873-883	processing	_	
4-12	884-886	of	_	
4-13	887-890	the	_	
4-14	891-894	VFT	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask	
4-15	894-895	.	_	

#Text=Further, it may be possible to extend the current VFT using this repetition to provide a more sensitive examination of the left PFC, whose dysfunction has been reported in several psychiatric diseases such as major depression, bipolar disorder, and schizophrenia.
5-1	896-903	Further	_	
5-2	903-904	,	_	
5-3	905-907	it	_	
5-4	908-911	may	_	
5-5	912-914	be	_	
5-6	915-923	possible	_	
5-7	924-926	to	_	
5-8	927-933	extend	_	
5-9	934-937	the	_	
5-10	938-945	current	_	
5-11	946-949	VFT	http://maven.renci.org/NeuroBridge/neurobridge#VerbalFluencyTask	
5-12	950-955	using	_	
5-13	956-960	this	_	
5-14	961-971	repetition	_	
5-15	972-974	to	_	
5-16	975-982	provide	_	
5-17	983-984	a	_	
5-18	985-989	more	_	
5-19	990-999	sensitive	_	
5-20	1000-1011	examination	_	
5-21	1012-1014	of	_	
5-22	1015-1018	the	_	
5-23	1019-1023	left	_	
5-24	1024-1027	PFC	_	
5-25	1027-1028	,	_	
5-26	1029-1034	whose	_	
5-27	1035-1046	dysfunction	_	
5-28	1047-1050	has	_	
5-29	1051-1055	been	_	
5-30	1056-1064	reported	_	
5-31	1065-1067	in	_	
5-32	1068-1075	several	_	
5-33	1076-1087	psychiatric	_	
5-34	1088-1096	diseases	_	
5-35	1097-1101	such	_	
5-36	1102-1104	as	_	
5-37	1105-1110	major	_	
5-38	1111-1121	depression	_	
5-39	1121-1122	,	_	
5-40	1123-1130	bipolar	_	
5-41	1131-1139	disorder	_	
5-42	1139-1140	,	_	
5-43	1141-1144	and	_	
5-44	1145-1158	schizophrenia	_	
5-45	1158-1159	.	_	

#Text=Introduction
#Text=On the basis of accumulating evidence regarding near-infrared spectroscopy (NIRS) as a promising simple neuroimaging modality to phenomenologically depict dynamic brain activation, the application of NIRS in psychiatric clinical settings in Japan has been discussed.
6-1	1160-1172	Introduction	_	
6-2	1173-1175	On	_	
6-3	1176-1179	the	_	
6-4	1180-1185	basis	_	
6-5	1186-1188	of	_	
6-6	1189-1201	accumulating	_	
6-7	1202-1210	evidence	_	
6-8	1211-1220	regarding	_	
6-9	1221-1234	near-infrared	_	
6-10	1235-1247	spectroscopy	_	
6-11	1248-1249	(	_	
6-12	1249-1253	NIRS	_	
6-13	1253-1254	)	_	
6-14	1255-1257	as	_	
6-15	1258-1259	a	_	
6-16	1260-1269	promising	_	
6-17	1270-1276	simple	_	
6-18	1277-1289	neuroimaging	_	
6-19	1290-1298	modality	_	
6-20	1299-1301	to	_	
6-21	1302-1320	phenomenologically	_	
6-22	1321-1327	depict	_	
6-23	1328-1335	dynamic	_	
6-24	1336-1341	brain	_	
6-25	1342-1352	activation	_	
6-26	1352-1353	,	_	
6-27	1354-1357	the	_	
6-28	1358-1369	application	_	
6-29	1370-1372	of	_	
6-30	1373-1377	NIRS	_	
6-31	1378-1380	in	_	
6-32	1381-1392	psychiatric	_	
6-33	1393-1401	clinical	_	
6-34	1402-1410	settings	_	
6-35	1411-1413	in	_	
6-36	1414-1419	Japan	_	
6-37	1420-1423	has	_	
6-38	1424-1428	been	_	
6-39	1429-1438	discussed	_	
6-40	1438-1439	.	_	

#Text=In a trial in Japan, a phonemic version of the verbal fluency test (VFT) was employed to capture prefrontal hemodynamic changes for the purpose of assisting differential diagnoses for major depressive disorder, bipolar disorder, and schizophrenia.
7-1	1440-1442	In	_	
7-2	1443-1444	a	_	
7-3	1445-1450	trial	_	
7-4	1451-1453	in	_	
7-5	1454-1459	Japan	_	
7-6	1459-1460	,	_	
7-7	1461-1462	a	_	
7-8	1463-1471	phonemic	_	
7-9	1472-1479	version	_	
7-10	1480-1482	of	_	
7-11	1483-1486	the	_	
7-12	1487-1493	verbal	_	
7-13	1494-1501	fluency	_	
7-14	1502-1506	test	_	
7-15	1507-1508	(	_	
7-16	1508-1511	VFT	_	
7-17	1511-1512	)	_	
7-18	1513-1516	was	_	
7-19	1517-1525	employed	_	
7-20	1526-1528	to	_	
7-21	1529-1536	capture	_	
7-22	1537-1547	prefrontal	_	
7-23	1548-1559	hemodynamic	_	
7-24	1560-1567	changes	_	
7-25	1568-1571	for	_	
7-26	1572-1575	the	_	
7-27	1576-1583	purpose	_	
7-28	1584-1586	of	_	
7-29	1587-1596	assisting	_	
7-30	1597-1609	differential	_	
7-31	1610-1619	diagnoses	_	
7-32	1620-1623	for	_	
7-33	1624-1629	major	_	
7-34	1630-1640	depressive	_	
7-35	1641-1649	disorder	_	
7-36	1649-1650	,	_	
7-37	1651-1658	bipolar	_	
7-38	1659-1667	disorder	_	
7-39	1667-1668	,	_	
7-40	1669-1672	and	_	
7-41	1673-1686	schizophrenia	_	
7-42	1686-1687	.	_	

#Text=The prefrontal activation pattern is characterized in this setting to be small, delayed, and distorted for major depression, bipolar disorder, and schizophrenia, respectively.
8-1	1688-1691	The	_	
8-2	1692-1702	prefrontal	_	
8-3	1703-1713	activation	_	
8-4	1714-1721	pattern	_	
8-5	1722-1724	is	_	
8-6	1725-1738	characterized	_	
8-7	1739-1741	in	_	
8-8	1742-1746	this	_	
8-9	1747-1754	setting	_	
8-10	1755-1757	to	_	
8-11	1758-1760	be	_	
8-12	1761-1766	small	_	
8-13	1766-1767	,	_	
8-14	1768-1775	delayed	_	
8-15	1775-1776	,	_	
8-16	1777-1780	and	_	
8-17	1781-1790	distorted	_	
8-18	1791-1794	for	_	
8-19	1795-1800	major	_	
8-20	1801-1811	depression	_	
8-21	1811-1812	,	_	
8-22	1813-1820	bipolar	_	
8-23	1821-1829	disorder	_	
8-24	1829-1830	,	_	
8-25	1831-1834	and	_	
8-26	1835-1848	schizophrenia	_	
8-27	1848-1849	,	_	
8-28	1850-1862	respectively	_	
8-29	1862-1863	.	_	

#Text=Although this trial has been partially successful in that the phonemic VFT has been approved as a medical examination by the health ministry in Japan, its accuracy remains to be improved, as demonstrated by the fact that the sensitivity of the distinguished prefrontal activation pattern is 52% for major depression (small activation), 66% for bipolar disorder (delayed activation), and 59% for schizophrenia (distorted activation).
9-1	1864-1872	Although	_	
9-2	1873-1877	this	_	
9-3	1878-1883	trial	_	
9-4	1884-1887	has	_	
9-5	1888-1892	been	_	
9-6	1893-1902	partially	_	
9-7	1903-1913	successful	_	
9-8	1914-1916	in	_	
9-9	1917-1921	that	_	
9-10	1922-1925	the	_	
9-11	1926-1934	phonemic	_	
9-12	1935-1938	VFT	_	
9-13	1939-1942	has	_	
9-14	1943-1947	been	_	
9-15	1948-1956	approved	_	
9-16	1957-1959	as	_	
9-17	1960-1961	a	_	
9-18	1962-1969	medical	_	
9-19	1970-1981	examination	_	
9-20	1982-1984	by	_	
9-21	1985-1988	the	_	
9-22	1989-1995	health	_	
9-23	1996-2004	ministry	_	
9-24	2005-2007	in	_	
9-25	2008-2013	Japan	_	
9-26	2013-2014	,	_	
9-27	2015-2018	its	_	
9-28	2019-2027	accuracy	_	
9-29	2028-2035	remains	_	
9-30	2036-2038	to	_	
9-31	2039-2041	be	_	
9-32	2042-2050	improved	_	
9-33	2050-2051	,	_	
9-34	2052-2054	as	_	
9-35	2055-2067	demonstrated	_	
9-36	2068-2070	by	_	
9-37	2071-2074	the	_	
9-38	2075-2079	fact	_	
9-39	2080-2084	that	_	
9-40	2085-2088	the	_	
9-41	2089-2100	sensitivity	_	
9-42	2101-2103	of	_	
9-43	2104-2107	the	_	
9-44	2108-2121	distinguished	_	
9-45	2122-2132	prefrontal	_	
9-46	2133-2143	activation	_	
9-47	2144-2151	pattern	_	
9-48	2152-2154	is	_	
9-49	2155-2158	52%	_	
9-50	2159-2162	for	_	
9-51	2163-2168	major	_	
9-52	2169-2179	depression	_	
9-53	2180-2181	(	_	
9-54	2181-2186	small	_	
9-55	2187-2197	activation	_	
9-56	2197-2198	)	_	
9-57	2198-2199	,	_	
9-58	2200-2203	66%	_	
9-59	2204-2207	for	_	
9-60	2208-2215	bipolar	_	
9-61	2216-2224	disorder	_	
9-62	2225-2226	(	_	
9-63	2226-2233	delayed	_	
9-64	2234-2244	activation	_	
9-65	2244-2245	)	_	
9-66	2245-2246	,	_	
9-67	2247-2250	and	_	
9-68	2251-2254	59%	_	
9-69	2255-2258	for	_	
9-70	2259-2272	schizophrenia	_	
9-71	2273-2274	(	_	
9-72	2274-2283	distorted	_	
9-73	2284-2294	activation	_	
9-74	2294-2295	)	_	
9-75	2295-2296	.	_	

#Text=Addressing this issue will require an understanding and further development of the current VFT that is qualified for medical examination in Japan, albeit not enough, to assist in the differential diagnosis of these diseases.
10-1	2297-2307	Addressing	_	
10-2	2308-2312	this	_	
10-3	2313-2318	issue	_	
10-4	2319-2323	will	_	
10-5	2324-2331	require	_	
10-6	2332-2334	an	_	
10-7	2335-2348	understanding	_	
10-8	2349-2352	and	_	
10-9	2353-2360	further	_	
10-10	2361-2372	development	_	
10-11	2373-2375	of	_	
10-12	2376-2379	the	_	
10-13	2380-2387	current	_	
10-14	2388-2391	VFT	_	
10-15	2392-2396	that	_	
10-16	2397-2399	is	_	
10-17	2400-2409	qualified	_	
10-18	2410-2413	for	_	
10-19	2414-2421	medical	_	
10-20	2422-2433	examination	_	
10-21	2434-2436	in	_	
10-22	2437-2442	Japan	_	
10-23	2442-2443	,	_	
10-24	2444-2450	albeit	_	
10-25	2451-2454	not	_	
10-26	2455-2461	enough	_	
10-27	2461-2462	,	_	
10-28	2463-2465	to	_	
10-29	2466-2472	assist	_	
10-30	2473-2475	in	_	
10-31	2476-2479	the	_	
10-32	2480-2492	differential	_	
10-33	2493-2502	diagnosis	_	
10-34	2503-2505	of	_	
10-35	2506-2511	these	_	
10-36	2512-2520	diseases	_	
10-37	2520-2521	.	_	

#Text=VFT consists of two dissociable phenomena of verbal fluency performance: (1) “clustering,” which generates semantically or phonemically related words within subcategories and (2) “switching,” which is the ability to shift efficiently to a new subcategory.
11-1	2522-2525	VFT	_	
11-2	2526-2534	consists	_	
11-3	2535-2537	of	_	
11-4	2538-2541	two	_	
11-5	2542-2553	dissociable	_	
11-6	2554-2563	phenomena	_	
11-7	2564-2566	of	_	
11-8	2567-2573	verbal	_	
11-9	2574-2581	fluency	_	
11-10	2582-2593	performance	_	
11-11	2593-2594	:	_	
11-12	2595-2596	(	_	
11-13	2596-2597	1	_	
11-14	2597-2598	)	_	
11-15	2599-2600	“	_	
11-16	2600-2610	clustering	_	
11-17	2610-2611	,	_	
11-18	2611-2612	”	_	
11-19	2613-2618	which	_	
11-20	2619-2628	generates	_	
11-21	2629-2641	semantically	_	
11-22	2642-2644	or	_	
11-23	2645-2657	phonemically	_	
11-24	2658-2665	related	_	
11-25	2666-2671	words	_	
11-26	2672-2678	within	_	
11-27	2679-2692	subcategories	_	
11-28	2693-2696	and	_	
11-29	2697-2698	(	_	
11-30	2698-2699	2	_	
11-31	2699-2700	)	_	
11-32	2701-2702	“	_	
11-33	2702-2711	switching	_	
11-34	2711-2712	,	_	
11-35	2712-2713	”	_	
11-36	2714-2719	which	_	
11-37	2720-2722	is	_	
11-38	2723-2726	the	_	
11-39	2727-2734	ability	_	
11-40	2735-2737	to	_	
11-41	2738-2743	shift	_	
11-42	2744-2755	efficiently	_	
11-43	2756-2758	to	_	
11-44	2759-2760	a	_	
11-45	2761-2764	new	_	
11-46	2765-2776	subcategory	_	
11-47	2776-2777	.	_	

#Text=Switching is particularly needed for word generation in phonemic VFT, whereas switching and clustering are equally important for semantic VFT.
12-1	2778-2787	Switching	_	
12-2	2788-2790	is	_	
12-3	2791-2803	particularly	_	
12-4	2804-2810	needed	_	
12-5	2811-2814	for	_	
12-6	2815-2819	word	_	
12-7	2820-2830	generation	_	
12-8	2831-2833	in	_	
12-9	2834-2842	phonemic	_	
12-10	2843-2846	VFT	_	
12-11	2846-2847	,	_	
12-12	2848-2855	whereas	_	
12-13	2856-2865	switching	_	
12-14	2866-2869	and	_	
12-15	2870-2880	clustering	_	
12-16	2881-2884	are	_	
12-17	2885-2892	equally	_	
12-18	2893-2902	important	_	
12-19	2903-2906	for	_	
12-20	2907-2915	semantic	_	
12-21	2916-2919	VFT	_	
12-22	2919-2920	.	_	

#Text=In accordance with these neuropsychological features of the two versions of the VFT, a direct comparison of the two tasks in positron emission tomography (PET) and fMRI studies has shown that phonemic VFT activates the prefrontal cortex (PFC) more strongly than does semantic VFT, because switching is primarily subserved by the PFC.
13-1	2921-2923	In	_	
13-2	2924-2934	accordance	_	
13-3	2935-2939	with	_	
13-4	2940-2945	these	_	
13-5	2946-2964	neuropsychological	_	
13-6	2965-2973	features	_	
13-7	2974-2976	of	_	
13-8	2977-2980	the	_	
13-9	2981-2984	two	_	
13-10	2985-2993	versions	_	
13-11	2994-2996	of	_	
13-12	2997-3000	the	_	
13-13	3001-3004	VFT	_	
13-14	3004-3005	,	_	
13-15	3006-3007	a	_	
13-16	3008-3014	direct	_	
13-17	3015-3025	comparison	_	
13-18	3026-3028	of	_	
13-19	3029-3032	the	_	
13-20	3033-3036	two	_	
13-21	3037-3042	tasks	_	
13-22	3043-3045	in	_	
13-23	3046-3054	positron	_	
13-24	3055-3063	emission	_	
13-25	3064-3074	tomography	_	
13-26	3075-3076	(	_	
13-27	3076-3079	PET	_	
13-28	3079-3080	)	_	
13-29	3081-3084	and	_	
13-30	3085-3089	fMRI	_	
13-31	3090-3097	studies	_	
13-32	3098-3101	has	_	
13-33	3102-3107	shown	_	
13-34	3108-3112	that	_	
13-35	3113-3121	phonemic	_	
13-36	3122-3125	VFT	_	
13-37	3126-3135	activates	_	
13-38	3136-3139	the	_	
13-39	3140-3150	prefrontal	_	
13-40	3151-3157	cortex	_	
13-41	3158-3159	(	_	
13-42	3159-3162	PFC	_	
13-43	3162-3163	)	_	
13-44	3164-3168	more	_	
13-45	3169-3177	strongly	_	
13-46	3178-3182	than	_	
13-47	3183-3187	does	_	
13-48	3188-3196	semantic	_	
13-49	3197-3200	VFT	_	
13-50	3200-3201	,	_	
13-51	3202-3209	because	_	
13-52	3210-3219	switching	_	
13-53	3220-3222	is	_	
13-54	3223-3232	primarily	_	
13-55	3233-3242	subserved	_	
13-56	3243-3245	by	_	
13-57	3246-3249	the	_	
13-58	3250-3253	PFC	_	
13-59	3253-3254	.	_	

#Text=A unique feature of the phonemic VFT currently used in Japanese clinical psychiatric settings is that it contains switching of designated syllables: three sets of syllables are designated in 20-s segments for each 60-s task period.
14-1	3255-3256	A	_	
14-2	3257-3263	unique	_	
14-3	3264-3271	feature	_	
14-4	3272-3274	of	_	
14-5	3275-3278	the	_	
14-6	3279-3287	phonemic	_	
14-7	3288-3291	VFT	_	
14-8	3292-3301	currently	_	
14-9	3302-3306	used	_	
14-10	3307-3309	in	_	
14-11	3310-3318	Japanese	_	
14-12	3319-3327	clinical	_	
14-13	3328-3339	psychiatric	_	
14-14	3340-3348	settings	_	
14-15	3349-3351	is	_	
14-16	3352-3356	that	_	
14-17	3357-3359	it	_	
14-18	3360-3368	contains	_	
14-19	3369-3378	switching	_	
14-20	3379-3381	of	_	
14-21	3382-3392	designated	_	
14-22	3393-3402	syllables	_	
14-23	3402-3403	:	_	
14-24	3404-3409	three	_	
14-25	3410-3414	sets	_	
14-26	3415-3417	of	_	
14-27	3418-3427	syllables	_	
14-28	3428-3431	are	_	
14-29	3432-3442	designated	_	
14-30	3443-3445	in	_	
14-31	3446-3448	20	_	
14-32	3448-3449	-	_	
14-33	3449-3450	s	_	
14-34	3451-3459	segments	_	
14-35	3460-3463	for	_	
14-36	3464-3468	each	_	
14-37	3469-3471	60	_	
14-38	3471-3472	-	_	
14-39	3472-3473	s	_	
14-40	3474-3478	task	_	
14-41	3479-3485	period	_	
14-42	3485-3486	.	_	

#Text=This is a modification of the standard-type phonemic VFT in which the designated syllable is constrained to one syllable for the entire 60-s task period.
15-1	3487-3491	This	_	
15-2	3492-3494	is	_	
15-3	3495-3496	a	_	
15-4	3497-3509	modification	_	
15-5	3510-3512	of	_	
15-6	3513-3516	the	_	
15-7	3517-3530	standard-type	_	
15-8	3531-3539	phonemic	_	
15-9	3540-3543	VFT	_	
15-10	3544-3546	in	_	
15-11	3547-3552	which	_	
15-12	3553-3556	the	_	
15-13	3557-3567	designated	_	
15-14	3568-3576	syllable	_	
15-15	3577-3579	is	_	
15-16	3580-3591	constrained	_	
15-17	3592-3594	to	_	
15-18	3595-3598	one	_	
15-19	3599-3607	syllable	_	
15-20	3608-3611	for	_	
15-21	3612-3615	the	_	
15-22	3616-3622	entire	_	
15-23	3623-3625	60	_	
15-24	3625-3626	-	_	
15-25	3626-3627	s	_	
15-26	3628-3632	task	_	
15-27	3633-3639	period	_	
15-28	3639-3640	.	_	

#Text=This modified VFT (m-VFT) may be a task that engages profound switching ability, because structurally, it contains switching of the syllables, and the phonemic VFT principally demands an intense switching ability.
16-1	3641-3645	This	_	
16-2	3646-3654	modified	_	
16-3	3655-3658	VFT	_	
16-4	3659-3660	(	_	
16-5	3660-3665	m-VFT	_	
16-6	3665-3666	)	_	
16-7	3667-3670	may	_	
16-8	3671-3673	be	_	
16-9	3674-3675	a	_	
16-10	3676-3680	task	_	
16-11	3681-3685	that	_	
16-12	3686-3693	engages	_	
16-13	3694-3702	profound	_	
16-14	3703-3712	switching	_	
16-15	3713-3720	ability	_	
16-16	3720-3721	,	_	
16-17	3722-3729	because	_	
16-18	3730-3742	structurally	_	
16-19	3742-3743	,	_	
16-20	3744-3746	it	_	
16-21	3747-3755	contains	_	
16-22	3756-3765	switching	_	
16-23	3766-3768	of	_	
16-24	3769-3772	the	_	
16-25	3773-3782	syllables	_	
16-26	3782-3783	,	_	
16-27	3784-3787	and	_	
16-28	3788-3791	the	_	
16-29	3792-3800	phonemic	_	
16-30	3801-3804	VFT	_	
16-31	3805-3816	principally	_	
16-32	3817-3824	demands	_	
16-33	3825-3827	an	_	
16-34	3828-3835	intense	_	
16-35	3836-3845	switching	_	
16-36	3846-3853	ability	_	
16-37	3853-3854	.	_	

#Text=These features of the m-VFT may specifically impact frontal cortical activation, which may, to some extent, allow validation of the m-VFT as an assistive device in the differential diagnosis of psychiatric diseases.
17-1	3855-3860	These	_	
17-2	3861-3869	features	_	
17-3	3870-3872	of	_	
17-4	3873-3876	the	_	
17-5	3877-3882	m-VFT	_	
17-6	3883-3886	may	_	
17-7	3887-3899	specifically	_	
17-8	3900-3906	impact	_	
17-9	3907-3914	frontal	_	
17-10	3915-3923	cortical	_	
17-11	3924-3934	activation	_	
17-12	3934-3935	,	_	
17-13	3936-3941	which	_	
17-14	3942-3945	may	_	
17-15	3945-3946	,	_	
17-16	3947-3949	to	_	
17-17	3950-3954	some	_	
17-18	3955-3961	extent	_	
17-19	3961-3962	,	_	
17-20	3963-3968	allow	_	
17-21	3969-3979	validation	_	
17-22	3980-3982	of	_	
17-23	3983-3986	the	_	
17-24	3987-3992	m-VFT	_	
17-25	3993-3995	as	_	
17-26	3996-3998	an	_	
17-27	3999-4008	assistive	_	
17-28	4009-4015	device	_	
17-29	4016-4018	in	_	
17-30	4019-4022	the	_	
17-31	4023-4035	differential	_	
17-32	4036-4045	diagnosis	_	
17-33	4046-4048	of	_	
17-34	4049-4060	psychiatric	_	
17-35	4061-4069	diseases	_	
17-36	4069-4070	.	_	

#Text=In this study, to extend the unique feature of this test, the m-VFT was repeated, and the change in hemodynamic activation of the PFC was investigated using NIRS.
18-1	4071-4073	In	_	
18-2	4074-4078	this	_	
18-3	4079-4084	study	_	
18-4	4084-4085	,	_	
18-5	4086-4088	to	_	
18-6	4089-4095	extend	_	
18-7	4096-4099	the	_	
18-8	4100-4106	unique	_	
18-9	4107-4114	feature	_	
18-10	4115-4117	of	_	
18-11	4118-4122	this	_	
18-12	4123-4127	test	_	
18-13	4127-4128	,	_	
18-14	4129-4132	the	_	
18-15	4133-4138	m-VFT	_	
18-16	4139-4142	was	_	
18-17	4143-4151	repeated	_	
18-18	4151-4152	,	_	
18-19	4153-4156	and	_	
18-20	4157-4160	the	_	
18-21	4161-4167	change	_	
18-22	4168-4170	in	_	
18-23	4171-4182	hemodynamic	_	
18-24	4183-4193	activation	_	
18-25	4194-4196	of	_	
18-26	4197-4200	the	_	
18-27	4201-4204	PFC	_	
18-28	4205-4208	was	_	
18-29	4209-4221	investigated	_	
18-30	4222-4227	using	_	
18-31	4228-4232	NIRS	_	
18-32	4232-4233	.	_	

#Text=Materials and methods
#Text=Subjects
#Text=Twenty healthy males (age: mean ± standard deviation [SD] = 28.2 ± 3.3 years) participated in this study.
19-1	4234-4243	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
19-2	4244-4247	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
19-3	4248-4255	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[3]	
19-4	4256-4264	Subjects	_	
19-5	4265-4271	Twenty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-6	4272-4279	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
19-7	4280-4285	males	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
19-8	4286-4287	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-9	4287-4290	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-10	4290-4291	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-11	4292-4296	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-12	4297-4298	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-13	4299-4307	standard	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-14	4308-4317	deviation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-15	4318-4319	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-16	4319-4321	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-17	4321-4322	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-18	4323-4324	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-19	4325-4329	28.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-20	4330-4331	±	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-21	4332-4335	3.3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-22	4336-4341	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-23	4341-4342	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-24	4343-4355	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-25	4356-4358	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-26	4359-4363	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-27	4364-4369	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
19-28	4369-4370	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=All were native Japanese speakers and were right handed, as indicated by their Edinburgh Inventory scores.
20-1	4371-4374	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-2	4375-4379	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-3	4380-4386	native	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-4	4387-4395	Japanese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-5	4396-4404	speakers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-6	4405-4408	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-7	4409-4413	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-8	4414-4419	right	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-9	4420-4426	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-10	4426-4427	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-11	4428-4430	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-12	4431-4440	indicated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-13	4441-4443	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-14	4444-4449	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-15	4450-4459	Edinburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[7]	
20-16	4460-4469	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#EdinburghHandednessInventoryQuestionnaire[7]	
20-17	4470-4476	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
20-18	4476-4477	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=After a complete description of the study was presented, written informed consent was obtained from all subjects.
21-1	4478-4483	After	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-2	4484-4485	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-3	4486-4494	complete	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-4	4495-4506	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-5	4507-4509	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-6	4510-4513	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-7	4514-4519	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-8	4520-4523	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-9	4524-4533	presented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-10	4533-4534	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-11	4535-4542	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-12	4543-4551	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-13	4552-4559	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-14	4560-4563	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-15	4564-4572	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-16	4573-4577	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-17	4578-4581	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-18	4582-4590	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
21-19	4590-4591	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=The present study was approved by the Ethics Committee of Kindai University Faculty of Medicine.
22-1	4592-4595	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-2	4596-4603	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-3	4604-4609	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-4	4610-4613	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-5	4614-4622	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-6	4623-4625	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-7	4626-4629	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-8	4630-4636	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-9	4637-4646	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-10	4647-4649	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-11	4650-4656	Kindai	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-12	4657-4667	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-13	4668-4675	Faculty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-14	4676-4678	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-15	4679-4687	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
22-16	4687-4688	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=NIRS
#Text=A 52-channel NIRS device, ETG-4000 Optical Topography System (Hitachi Medical Co., Tokyo, Japan), was used to measure relative changes in oxy- and deoxy-hemoglobin (Hb) concentrations using two wavelengths (695 and 830 nm) with a sampling rate of 100 ms.
23-1	4689-4693	NIRS	_	
23-2	4694-4695	A	_	
23-3	4696-4698	52	_	
23-4	4698-4699	-	_	
23-5	4699-4706	channel	_	
23-6	4707-4711	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
23-7	4712-4718	device	_	
23-8	4718-4719	,	_	
23-9	4720-4723	ETG	_	
23-10	4723-4724	-	_	
23-11	4724-4728	4000	_	
23-12	4729-4736	Optical	_	
23-13	4737-4747	Topography	_	
23-14	4748-4754	System	_	
23-15	4755-4756	(	_	
23-16	4756-4763	Hitachi	_	
23-17	4764-4771	Medical	_	
23-18	4772-4774	Co	_	
23-19	4774-4775	.	_	
23-20	4775-4776	,	_	
23-21	4777-4782	Tokyo	_	
23-22	4782-4783	,	_	
23-23	4784-4789	Japan	_	
23-24	4789-4790	)	_	
23-25	4790-4791	,	_	
23-26	4792-4795	was	_	
23-27	4796-4800	used	_	
23-28	4801-4803	to	_	
23-29	4804-4811	measure	_	
23-30	4812-4820	relative	_	
23-31	4821-4828	changes	_	
23-32	4829-4831	in	_	
23-33	4832-4835	oxy	_	
23-34	4835-4836	-	_	
23-35	4837-4840	and	_	
23-36	4841-4857	deoxy-hemoglobin	_	
23-37	4858-4859	(	_	
23-38	4859-4861	Hb	_	
23-39	4861-4862	)	_	
23-40	4863-4877	concentrations	_	
23-41	4878-4883	using	_	
23-42	4884-4887	two	_	
23-43	4888-4899	wavelengths	_	
23-44	4900-4901	(	_	
23-45	4901-4904	695	_	
23-46	4905-4908	and	_	
23-47	4909-4912	830	_	
23-48	4913-4915	nm	_	
23-49	4915-4916	)	_	
23-50	4917-4921	with	_	
23-51	4922-4923	a	_	
23-52	4924-4932	sampling	_	
23-53	4933-4937	rate	_	
23-54	4938-4940	of	_	
23-55	4941-4944	100	_	
23-56	4945-4947	ms	_	
23-57	4947-4948	.	_	

#Text=Optical data were analyzed with the modified Beer–Lambert law to calculate the signals reflecting changes of Hb levels in arbitrary units (mM–mm).
24-1	4949-4956	Optical	_	
24-2	4957-4961	data	_	
24-3	4962-4966	were	_	
24-4	4967-4975	analyzed	_	
24-5	4976-4980	with	_	
24-6	4981-4984	the	_	
24-7	4985-4993	modified	_	
24-8	4994-5006	Beer–Lambert	_	
24-9	5007-5010	law	_	
24-10	5011-5013	to	_	
24-11	5014-5023	calculate	_	
24-12	5024-5027	the	_	
24-13	5028-5035	signals	_	
24-14	5036-5046	reflecting	_	
24-15	5047-5054	changes	_	
24-16	5055-5057	of	_	
24-17	5058-5060	Hb	_	
24-18	5061-5067	levels	_	
24-19	5068-5070	in	_	
24-20	5071-5080	arbitrary	_	
24-21	5081-5086	units	_	
24-22	5087-5088	(	_	
24-23	5088-5093	mM–mm	_	
24-24	5093-5094	)	_	
24-25	5094-5095	.	_	

#Text=NIRS probes were fixed using 3 × 11 thermoplastic shells, with the lowest probes positioned along the Fp1–Fp2 line according to the International 10–20 system.
25-1	5096-5100	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
25-2	5101-5107	probes	_	
25-3	5108-5112	were	_	
25-4	5113-5118	fixed	_	
25-5	5119-5124	using	_	
25-6	5125-5126	3	_	
25-7	5127-5128	×	_	
25-8	5129-5131	11	_	
25-9	5132-5145	thermoplastic	_	
25-10	5146-5152	shells	_	
25-11	5152-5153	,	_	
25-12	5154-5158	with	_	
25-13	5159-5162	the	_	
25-14	5163-5169	lowest	_	
25-15	5170-5176	probes	_	
25-16	5177-5187	positioned	_	
25-17	5188-5193	along	_	
25-18	5194-5197	the	_	
25-19	5198-5201	Fp1	_	
25-20	5201-5202	–	_	
25-21	5202-5205	Fp2	_	
25-22	5206-5210	line	_	
25-23	5211-5220	according	_	
25-24	5221-5223	to	_	
25-25	5224-5227	the	_	
25-26	5228-5241	International	_	
25-27	5242-5244	10	_	
25-28	5244-5245	–	_	
25-29	5245-5247	20	_	
25-30	5248-5254	system	_	
25-31	5254-5255	.	_	

#Text=The distance between pairs of emission and detector probes was set at 3.0 cm, and the measurement area between the probes was defined as a channel.
26-1	5256-5259	The	_	
26-2	5260-5268	distance	_	
26-3	5269-5276	between	_	
26-4	5277-5282	pairs	_	
26-5	5283-5285	of	_	
26-6	5286-5294	emission	_	
26-7	5295-5298	and	_	
26-8	5299-5307	detector	_	
26-9	5308-5314	probes	_	
26-10	5315-5318	was	_	
26-11	5319-5322	set	_	
26-12	5323-5325	at	_	
26-13	5326-5329	3.0	_	
26-14	5330-5332	cm	_	
26-15	5332-5333	,	_	
26-16	5334-5337	and	_	
26-17	5338-5341	the	_	
26-18	5342-5353	measurement	_	
26-19	5354-5358	area	_	
26-20	5359-5366	between	_	
26-21	5367-5370	the	_	
26-22	5371-5377	probes	_	
26-23	5378-5381	was	_	
26-24	5382-5389	defined	_	
26-25	5390-5392	as	_	
26-26	5393-5394	a	_	
26-27	5395-5402	channel	_	
26-28	5402-5403	.	_	

#Text=The arrangement of channels covered a portion of the bilateral prefrontal and temporal regions (S1 Fig), where they measured Hb signals of the cortical surface at a depth of 2–3 cm from the scalp.
27-1	5404-5407	The	_	
27-2	5408-5419	arrangement	_	
27-3	5420-5422	of	_	
27-4	5423-5431	channels	_	
27-5	5432-5439	covered	_	
27-6	5440-5441	a	_	
27-7	5442-5449	portion	_	
27-8	5450-5452	of	_	
27-9	5453-5456	the	_	
27-10	5457-5466	bilateral	_	
27-11	5467-5477	prefrontal	_	
27-12	5478-5481	and	_	
27-13	5482-5490	temporal	_	
27-14	5491-5498	regions	_	
27-15	5499-5500	(	_	
27-16	5500-5502	S1	_	
27-17	5503-5506	Fig	_	
27-18	5506-5507	)	_	
27-19	5507-5508	,	_	
27-20	5509-5514	where	_	
27-21	5515-5519	they	_	
27-22	5520-5528	measured	_	
27-23	5529-5531	Hb	_	
27-24	5532-5539	signals	_	
27-25	5540-5542	of	_	
27-26	5543-5546	the	_	
27-27	5547-5555	cortical	_	
27-28	5556-5563	surface	_	
27-29	5564-5566	at	_	
27-30	5567-5568	a	_	
27-31	5569-5574	depth	_	
27-32	5575-5577	of	_	
27-33	5578-5579	2	_	
27-34	5579-5580	–	_	
27-35	5580-5581	3	_	
27-36	5582-5584	cm	_	
27-37	5585-5589	from	_	
27-38	5590-5593	the	_	
27-39	5594-5599	scalp	_	
27-40	5599-5600	.	_	

#Text=This experimental setup was corroborated by a multi-individual study of the anatomical craniocerebral correction using the International 10–20 system.
28-1	5601-5605	This	_	
28-2	5606-5618	experimental	_	
28-3	5619-5624	setup	_	
28-4	5625-5628	was	_	
28-5	5629-5641	corroborated	_	
28-6	5642-5644	by	_	
28-7	5645-5646	a	_	
28-8	5647-5663	multi-individual	_	
28-9	5664-5669	study	_	
28-10	5670-5672	of	_	
28-11	5673-5676	the	_	
28-12	5677-5687	anatomical	_	
28-13	5688-5702	craniocerebral	_	
28-14	5703-5713	correction	_	
28-15	5714-5719	using	_	
28-16	5720-5723	the	_	
28-17	5724-5737	International	_	
28-18	5738-5740	10	_	
28-19	5740-5741	–	_	
28-20	5741-5743	20	_	
28-21	5744-5750	system	_	
28-22	5750-5751	.	_	

#Text=NIRS data analysis was performed according to the manual for clinical psychiatric settings in Japan for NIRS measurements, as shown in previous reports.
29-1	5752-5756	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
29-2	5757-5761	data	_	
29-3	5762-5770	analysis	_	
29-4	5771-5774	was	_	
29-5	5775-5784	performed	_	
29-6	5785-5794	according	_	
29-7	5795-5797	to	_	
29-8	5798-5801	the	_	
29-9	5802-5808	manual	_	
29-10	5809-5812	for	_	
29-11	5813-5821	clinical	_	
29-12	5822-5833	psychiatric	_	
29-13	5834-5842	settings	_	
29-14	5843-5845	in	_	
29-15	5846-5851	Japan	_	
29-16	5852-5855	for	_	
29-17	5856-5860	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
29-18	5861-5873	measurements	_	
29-19	5873-5874	,	_	
29-20	5875-5877	as	_	
29-21	5878-5883	shown	_	
29-22	5884-5886	in	_	
29-23	5887-5895	previous	_	
29-24	5896-5903	reports	_	
29-25	5903-5904	.	_	

#Text=Briefly, relative changes of oxy-Hb data were analyzed to estimate regional brain activation, and the mean oxy-Hb signals during the task period were analyzed using the “integral mode”: the pre-task baseline level was defined as the mean oxy-Hb measured for 10 s immediately before the task period, the post-task baseline level was defined as the mean oxy-Hb for the last 5 s in the post-task period, and linear fitting was then applied to the data between these pre- and post-task baseline levels.
30-1	5905-5912	Briefly	_	
30-2	5912-5913	,	_	
30-3	5914-5922	relative	_	
30-4	5923-5930	changes	_	
30-5	5931-5933	of	_	
30-6	5934-5940	oxy-Hb	_	
30-7	5941-5945	data	_	
30-8	5946-5950	were	_	
30-9	5951-5959	analyzed	_	
30-10	5960-5962	to	_	
30-11	5963-5971	estimate	_	
30-12	5972-5980	regional	_	
30-13	5981-5986	brain	_	
30-14	5987-5997	activation	_	
30-15	5997-5998	,	_	
30-16	5999-6002	and	_	
30-17	6003-6006	the	_	
30-18	6007-6011	mean	_	
30-19	6012-6018	oxy-Hb	_	
30-20	6019-6026	signals	_	
30-21	6027-6033	during	_	
30-22	6034-6037	the	_	
30-23	6038-6042	task	_	
30-24	6043-6049	period	_	
30-25	6050-6054	were	_	
30-26	6055-6063	analyzed	_	
30-27	6064-6069	using	_	
30-28	6070-6073	the	_	
30-29	6074-6075	“	_	
30-30	6075-6083	integral	_	
30-31	6084-6088	mode	_	
30-32	6088-6089	”	_	
30-33	6089-6090	:	_	
30-34	6091-6094	the	_	
30-35	6095-6103	pre-task	_	
30-36	6104-6112	baseline	_	
30-37	6113-6118	level	_	
30-38	6119-6122	was	_	
30-39	6123-6130	defined	_	
30-40	6131-6133	as	_	
30-41	6134-6137	the	_	
30-42	6138-6142	mean	_	
30-43	6143-6149	oxy-Hb	_	
30-44	6150-6158	measured	_	
30-45	6159-6162	for	_	
30-46	6163-6165	10	_	
30-47	6166-6167	s	_	
30-48	6168-6179	immediately	_	
30-49	6180-6186	before	_	
30-50	6187-6190	the	_	
30-51	6191-6195	task	_	
30-52	6196-6202	period	_	
30-53	6202-6203	,	_	
30-54	6204-6207	the	_	
30-55	6208-6217	post-task	_	
30-56	6218-6226	baseline	_	
30-57	6227-6232	level	_	
30-58	6233-6236	was	_	
30-59	6237-6244	defined	_	
30-60	6245-6247	as	_	
30-61	6248-6251	the	_	
30-62	6252-6256	mean	_	
30-63	6257-6263	oxy-Hb	_	
30-64	6264-6267	for	_	
30-65	6268-6271	the	_	
30-66	6272-6276	last	_	
30-67	6277-6278	5	_	
30-68	6279-6280	s	_	
30-69	6281-6283	in	_	
30-70	6284-6287	the	_	
30-71	6288-6297	post-task	_	
30-72	6298-6304	period	_	
30-73	6304-6305	,	_	
30-74	6306-6309	and	_	
30-75	6310-6316	linear	_	
30-76	6317-6324	fitting	_	
30-77	6325-6328	was	_	
30-78	6329-6333	then	_	
30-79	6334-6341	applied	_	
30-80	6342-6344	to	_	
30-81	6345-6348	the	_	
30-82	6349-6353	data	_	
30-83	6354-6361	between	_	
30-84	6362-6367	these	_	
30-85	6368-6371	pre	_	
30-86	6371-6372	-	_	
30-87	6373-6376	and	_	
30-88	6377-6386	post-task	_	
30-89	6387-6395	baseline	_	
30-90	6396-6402	levels	_	
30-91	6402-6403	.	_	

#Text=A 5-s moving average was calculated to eliminate any short-term motion artifacts.
31-1	6404-6405	A	_	
31-2	6406-6407	5	_	
31-3	6407-6408	-	_	
31-4	6408-6409	s	_	
31-5	6410-6416	moving	_	
31-6	6417-6424	average	_	
31-7	6425-6428	was	_	
31-8	6429-6439	calculated	_	
31-9	6440-6442	to	_	
31-10	6443-6452	eliminate	_	
31-11	6453-6456	any	_	
31-12	6457-6467	short-term	_	
31-13	6468-6474	motion	_	
31-14	6475-6484	artifacts	_	
31-15	6484-6485	.	_	

#Text=Based on previous NIRS studies, the data acquired from the 21 channels in the upper two rows were excluded from statistical analysis, because they clearly contained artifacts, presumably because of the presence of hair and also because their signal-to-noise ratio seemed to be low or approaching zero.
32-1	6486-6491	Based	_	
32-2	6492-6494	on	_	
32-3	6495-6503	previous	_	
32-4	6504-6508	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
32-5	6509-6516	studies	_	
32-6	6516-6517	,	_	
32-7	6518-6521	the	_	
32-8	6522-6526	data	_	
32-9	6527-6535	acquired	_	
32-10	6536-6540	from	_	
32-11	6541-6544	the	_	
32-12	6545-6547	21	_	
32-13	6548-6556	channels	_	
32-14	6557-6559	in	_	
32-15	6560-6563	the	_	
32-16	6564-6569	upper	_	
32-17	6570-6573	two	_	
32-18	6574-6578	rows	_	
32-19	6579-6583	were	_	
32-20	6584-6592	excluded	_	
32-21	6593-6597	from	_	
32-22	6598-6609	statistical	_	
32-23	6610-6618	analysis	_	
32-24	6618-6619	,	_	
32-25	6620-6627	because	_	
32-26	6628-6632	they	_	
32-27	6633-6640	clearly	_	
32-28	6641-6650	contained	_	
32-29	6651-6660	artifacts	_	
32-30	6660-6661	,	_	
32-31	6662-6672	presumably	_	
32-32	6673-6680	because	_	
32-33	6681-6683	of	_	
32-34	6684-6687	the	_	
32-35	6688-6696	presence	_	
32-36	6697-6699	of	_	
32-37	6700-6704	hair	_	
32-38	6705-6708	and	_	
32-39	6709-6713	also	_	
32-40	6714-6721	because	_	
32-41	6722-6727	their	_	
32-42	6728-6743	signal-to-noise	_	
32-43	6744-6749	ratio	_	
32-44	6750-6756	seemed	_	
32-45	6757-6759	to	_	
32-46	6760-6762	be	_	
32-47	6763-6766	low	_	
32-48	6767-6769	or	_	
32-49	6770-6781	approaching	_	
32-50	6782-6786	zero	_	
32-51	6786-6787	.	_	

#Text=Cognitive task
#Text=NIRS measurements were conducted using a series of three m-VFT sessions.
33-1	6788-6797	Cognitive	_	
33-2	6798-6802	task	_	
33-3	6803-6807	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
33-4	6808-6820	measurements	_	
33-5	6821-6825	were	_	
33-6	6826-6835	conducted	_	
33-7	6836-6841	using	_	
33-8	6842-6843	a	_	
33-9	6844-6850	series	_	
33-10	6851-6853	of	_	
33-11	6854-6859	three	_	
33-12	6860-6865	m-VFT	_	
33-13	6866-6874	sessions	_	
33-14	6874-6875	.	_	

#Text=Each m-VFT session was performed according to previous reports, and included a 30-s pre-task baseline period, a 60-s task period comprising three 20-s blocks, and a 70-s post-task baseline period (Fig 1).
34-1	6876-6880	Each	_	
34-2	6881-6886	m-VFT	_	
34-3	6887-6894	session	_	
34-4	6895-6898	was	_	
34-5	6899-6908	performed	_	
34-6	6909-6918	according	_	
34-7	6919-6921	to	_	
34-8	6922-6930	previous	_	
34-9	6931-6938	reports	_	
34-10	6938-6939	,	_	
34-11	6940-6943	and	_	
34-12	6944-6952	included	_	
34-13	6953-6954	a	_	
34-14	6955-6957	30	_	
34-15	6957-6958	-	_	
34-16	6958-6959	s	_	
34-17	6960-6968	pre-task	_	
34-18	6969-6977	baseline	_	
34-19	6978-6984	period	_	
34-20	6984-6985	,	_	
34-21	6986-6987	a	_	
34-22	6988-6990	60	_	
34-23	6990-6991	-	_	
34-24	6991-6992	s	_	
34-25	6993-6997	task	_	
34-26	6998-7004	period	_	
34-27	7005-7015	comprising	_	
34-28	7016-7021	three	_	
34-29	7022-7024	20	_	
34-30	7024-7025	-	_	
34-31	7025-7026	s	_	
34-32	7027-7033	blocks	_	
34-33	7033-7034	,	_	
34-34	7035-7038	and	_	
34-35	7039-7040	a	_	
34-36	7041-7043	70	_	
34-37	7043-7044	-	_	
34-38	7044-7045	s	_	
34-39	7046-7055	post-task	_	
34-40	7056-7064	baseline	_	
34-41	7065-7071	period	_	
34-42	7072-7073	(	_	
34-43	7073-7076	Fig	_	
34-44	7077-7078	1	_	
34-45	7078-7079	)	_	
34-46	7079-7080	.	_	

#Text=Subjects were instructed to repeat a sequence of syllables (a, i, u, e, o) during the pre-task and post-task baseline periods.
35-1	7081-7089	Subjects	_	
35-2	7090-7094	were	_	
35-3	7095-7105	instructed	_	
35-4	7106-7108	to	_	
35-5	7109-7115	repeat	_	
35-6	7116-7117	a	_	
35-7	7118-7126	sequence	_	
35-8	7127-7129	of	_	
35-9	7130-7139	syllables	_	
35-10	7140-7141	(	_	
35-11	7141-7142	a	_	
35-12	7142-7143	,	_	
35-13	7144-7145	i	_	
35-14	7145-7146	,	_	
35-15	7147-7148	u	_	
35-16	7148-7149	,	_	
35-17	7150-7151	e	_	
35-18	7151-7152	,	_	
35-19	7153-7154	o	_	
35-20	7154-7155	)	_	
35-21	7156-7162	during	_	
35-22	7163-7166	the	_	
35-23	7167-7175	pre-task	_	
35-24	7176-7179	and	_	
35-25	7180-7189	post-task	_	
35-26	7190-7198	baseline	_	
35-27	7199-7206	periods	_	
35-28	7206-7207	.	_	

#Text=During the task, subjects were asked to generate as many words as possible starting with the presented syllable on a computer display placed in front of them.
36-1	7208-7214	During	_	
36-2	7215-7218	the	_	
36-3	7219-7223	task	_	
36-4	7223-7224	,	_	
36-5	7225-7233	subjects	_	
36-6	7234-7238	were	_	
36-7	7239-7244	asked	_	
36-8	7245-7247	to	_	
36-9	7248-7256	generate	_	
36-10	7257-7259	as	_	
36-11	7260-7264	many	_	
36-12	7265-7270	words	_	
36-13	7271-7273	as	_	
36-14	7274-7282	possible	_	
36-15	7283-7291	starting	_	
36-16	7292-7296	with	_	
36-17	7297-7300	the	_	
36-18	7301-7310	presented	_	
36-19	7311-7319	syllable	_	
36-20	7320-7322	on	_	
36-21	7323-7324	a	_	
36-22	7325-7333	computer	_	
36-23	7334-7341	display	_	
36-24	7342-7348	placed	_	
36-25	7349-7351	in	_	
36-26	7352-7357	front	_	
36-27	7358-7360	of	_	
36-28	7361-7365	them	_	
36-29	7365-7366	.	_	

#Text=Generated words were marked as either correct or incorrect; the number of correct words represented the subject’s performance score in the task.
37-1	7367-7376	Generated	_	
37-2	7377-7382	words	_	
37-3	7383-7387	were	_	
37-4	7388-7394	marked	_	
37-5	7395-7397	as	_	
37-6	7398-7404	either	_	
37-7	7405-7412	correct	_	
37-8	7413-7415	or	_	
37-9	7416-7425	incorrect	_	
37-10	7425-7426	;	_	
37-11	7427-7430	the	_	
37-12	7431-7437	number	_	
37-13	7438-7440	of	_	
37-14	7441-7448	correct	_	
37-15	7449-7454	words	_	
37-16	7455-7466	represented	_	
37-17	7467-7470	the	_	
37-18	7471-7478	subject	_	
37-19	7478-7479	’	_	
37-20	7479-7480	s	_	
37-21	7481-7492	performance	_	
37-22	7493-7498	score	_	
37-23	7499-7501	in	_	
37-24	7502-7505	the	_	
37-25	7506-7510	task	_	
37-26	7510-7511	.	_	

#Text=As Fig 1 shows, a series of three sessions of the m-VFT were repeated, switching the designated syllables to avoid repetition of the same stimuli.
38-1	7512-7514	As	_	
38-2	7515-7518	Fig	_	
38-3	7519-7520	1	_	
38-4	7521-7526	shows	_	
38-5	7526-7527	,	_	
38-6	7528-7529	a	_	
38-7	7530-7536	series	_	
38-8	7537-7539	of	_	
38-9	7540-7545	three	_	
38-10	7546-7554	sessions	_	
38-11	7555-7557	of	_	
38-12	7558-7561	the	_	
38-13	7562-7567	m-VFT	_	
38-14	7568-7572	were	_	
38-15	7573-7581	repeated	_	
38-16	7581-7582	,	_	
38-17	7583-7592	switching	_	
38-18	7593-7596	the	_	
38-19	7597-7607	designated	_	
38-20	7608-7617	syllables	_	
38-21	7618-7620	to	_	
38-22	7621-7626	avoid	_	
38-23	7627-7637	repetition	_	
38-24	7638-7640	of	_	
38-25	7641-7644	the	_	
38-26	7645-7649	same	_	
38-27	7650-7657	stimuli	_	
38-28	7657-7658	.	_	

#Text=One of the three syllables was assigned to block 1 (seconds 0–20): /a/, /to/, or /na/; block 2 (seconds 20–40): /i/, /ki/, or /se/; and block 3 (seconds 40–60): /o/, /ta/, or /ha/.
39-1	7659-7662	One	_	
39-2	7663-7665	of	_	
39-3	7666-7669	the	_	
39-4	7670-7675	three	_	
39-5	7676-7685	syllables	_	
39-6	7686-7689	was	_	
39-7	7690-7698	assigned	_	
39-8	7699-7701	to	_	
39-9	7702-7707	block	_	
39-10	7708-7709	1	_	
39-11	7710-7711	(	_	
39-12	7711-7718	seconds	_	
39-13	7719-7720	0	_	
39-14	7720-7721	–	_	
39-15	7721-7723	20	_	
39-16	7723-7724	)	_	
39-17	7724-7725	:	_	
39-18	7726-7727	/	_	
39-19	7727-7728	a	_	
39-20	7728-7729	/	_	
39-21	7729-7730	,	_	
39-22	7731-7732	/	_	
39-23	7732-7734	to	_	
39-24	7734-7735	/	_	
39-25	7735-7736	,	_	
39-26	7737-7739	or	_	
39-27	7740-7741	/	_	
39-28	7741-7743	na	_	
39-29	7743-7744	/	_	
39-30	7744-7745	;	_	
39-31	7746-7751	block	_	
39-32	7752-7753	2	_	
39-33	7754-7755	(	_	
39-34	7755-7762	seconds	_	
39-35	7763-7765	20	_	
39-36	7765-7766	–	_	
39-37	7766-7768	40	_	
39-38	7768-7769	)	_	
39-39	7769-7770	:	_	
39-40	7771-7772	/	_	
39-41	7772-7773	i	_	
39-42	7773-7774	/	_	
39-43	7774-7775	,	_	
39-44	7776-7777	/	_	
39-45	7777-7779	ki	_	
39-46	7779-7780	/	_	
39-47	7780-7781	,	_	
39-48	7782-7784	or	_	
39-49	7785-7786	/	_	
39-50	7786-7788	se	_	
39-51	7788-7789	/	_	
39-52	7789-7790	;	_	
39-53	7791-7794	and	_	
39-54	7795-7800	block	_	
39-55	7801-7802	3	_	
39-56	7803-7804	(	_	
39-57	7804-7811	seconds	_	
39-58	7812-7814	40	_	
39-59	7814-7815	–	_	
39-60	7815-7817	60	_	
39-61	7817-7818	)	_	
39-62	7818-7819	:	_	
39-63	7820-7821	/	_	
39-64	7821-7822	o	_	
39-65	7822-7823	/	_	
39-66	7823-7824	,	_	
39-67	7825-7826	/	_	
39-68	7826-7828	ta	_	
39-69	7828-7829	/	_	
39-70	7829-7830	,	_	
39-71	7831-7833	or	_	
39-72	7834-7835	/	_	
39-73	7835-7837	ha	_	
39-74	7837-7838	/	_	
39-75	7838-7839	.	_	

#Text=Three-min rest intervals were taken between the m-VFT sessions.
40-1	7840-7849	Three-min	_	
40-2	7850-7854	rest	_	
40-3	7855-7864	intervals	_	
40-4	7865-7869	were	_	
40-5	7870-7875	taken	_	
40-6	7876-7883	between	_	
40-7	7884-7887	the	_	
40-8	7888-7893	m-VFT	_	
40-9	7894-7902	sessions	_	
40-10	7902-7903	.	_	

#Text=Throughout the three m-VFT sessions, NIRS probes were not removed to avoid changing the optical path length of the probes.
41-1	7904-7914	Throughout	_	
41-2	7915-7918	the	_	
41-3	7919-7924	three	_	
41-4	7925-7930	m-VFT	_	
41-5	7931-7939	sessions	_	
41-6	7939-7940	,	_	
41-7	7941-7945	NIRS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalNearInfraredSpectroscopy	
41-8	7946-7952	probes	_	
41-9	7953-7957	were	_	
41-10	7958-7961	not	_	
41-11	7962-7969	removed	_	
41-12	7970-7972	to	_	
41-13	7973-7978	avoid	_	
41-14	7979-7987	changing	_	
41-15	7988-7991	the	_	
41-16	7992-7999	optical	_	
41-17	8000-8004	path	_	
41-18	8005-8011	length	_	
41-19	8012-8014	of	_	
41-20	8015-8018	the	_	
41-21	8019-8025	probes	_	
41-22	8025-8026	.	_	

#Text=Design of the m-VFT set.
42-1	8027-8033	Design	_	
42-2	8034-8036	of	_	
42-3	8037-8040	the	_	
42-4	8041-8046	m-VFT	_	
42-5	8047-8050	set	_	
42-6	8050-8051	.	_	

#Text=Data analysis
#Text=Performance scores were compared among the three m-VFT sessions using repeated measures analysis of variance (ANOVA) with the Greenhouse-Geisser correction.
43-1	8052-8056	Data	_	
43-2	8057-8065	analysis	_	
43-3	8066-8077	Performance	_	
43-4	8078-8084	scores	_	
43-5	8085-8089	were	_	
43-6	8090-8098	compared	_	
43-7	8099-8104	among	_	
43-8	8105-8108	the	_	
43-9	8109-8114	three	_	
43-10	8115-8120	m-VFT	_	
43-11	8121-8129	sessions	_	
43-12	8130-8135	using	_	
43-13	8136-8144	repeated	_	
43-14	8145-8153	measures	_	
43-15	8154-8162	analysis	_	
43-16	8163-8165	of	_	
43-17	8166-8174	variance	_	
43-18	8175-8176	(	_	
43-19	8176-8181	ANOVA	_	
43-20	8181-8182	)	_	
43-21	8183-8187	with	_	
43-22	8188-8191	the	_	
43-23	8192-8210	Greenhouse-Geisser	_	
43-24	8211-8221	correction	_	
43-25	8221-8222	.	_	

#Text=Similarly, mean oxy-Hb signals were compared among the three m-VFT sessions across all subjects using repeated-measures ANOVA with the Greenhouse-Geisser correction.
44-1	8223-8232	Similarly	_	
44-2	8232-8233	,	_	
44-3	8234-8238	mean	_	
44-4	8239-8245	oxy-Hb	_	
44-5	8246-8253	signals	_	
44-6	8254-8258	were	_	
44-7	8259-8267	compared	_	
44-8	8268-8273	among	_	
44-9	8274-8277	the	_	
44-10	8278-8283	three	_	
44-11	8284-8289	m-VFT	_	
44-12	8290-8298	sessions	_	
44-13	8299-8305	across	_	
44-14	8306-8309	all	_	
44-15	8310-8318	subjects	_	
44-16	8319-8324	using	_	
44-17	8325-8342	repeated-measures	_	
44-18	8343-8348	ANOVA	_	
44-19	8349-8353	with	_	
44-20	8354-8357	the	_	
44-21	8358-8376	Greenhouse-Geisser	_	
44-22	8377-8387	correction	_	
44-23	8387-8388	.	_	

#Text=If this ANOVA yielded significance, Dunnett’s post-hoc multiple comparison test was conducted to detect a significant change in the second or third compared with the first m-VFT session.
45-1	8389-8391	If	_	
45-2	8392-8396	this	_	
45-3	8397-8402	ANOVA	_	
45-4	8403-8410	yielded	_	
45-5	8411-8423	significance	_	
45-6	8423-8424	,	_	
45-7	8425-8432	Dunnett	_	
45-8	8432-8433	’	_	
45-9	8433-8434	s	_	
45-10	8435-8443	post-hoc	_	
45-11	8444-8452	multiple	_	
45-12	8453-8463	comparison	_	
45-13	8464-8468	test	_	
45-14	8469-8472	was	_	
45-15	8473-8482	conducted	_	
45-16	8483-8485	to	_	
45-17	8486-8492	detect	_	
45-18	8493-8494	a	_	
45-19	8495-8506	significant	_	
45-20	8507-8513	change	_	
45-21	8514-8516	in	_	
45-22	8517-8520	the	_	
45-23	8521-8527	second	_	
45-24	8528-8530	or	_	
45-25	8531-8536	third	_	
45-26	8537-8545	compared	_	
45-27	8546-8550	with	_	
45-28	8551-8554	the	_	
45-29	8555-8560	first	_	
45-30	8561-8566	m-VFT	_	
45-31	8567-8574	session	_	
45-32	8574-8575	.	_	

#Text=Because we examined a total of 31 channels (referred to as “ch22-52” throughout) in the lower three rows, the threshold for significance of p-values was set at 0.0016 (0.05/31) using the Bonferroni correction.
46-1	8576-8583	Because	_	
46-2	8584-8586	we	_	
46-3	8587-8595	examined	_	
46-4	8596-8597	a	_	
46-5	8598-8603	total	_	
46-6	8604-8606	of	_	
46-7	8607-8609	31	_	
46-8	8610-8618	channels	_	
46-9	8619-8620	(	_	
46-10	8620-8628	referred	_	
46-11	8629-8631	to	_	
46-12	8632-8634	as	_	
46-13	8635-8636	“	_	
46-14	8636-8640	ch22	_	
46-15	8640-8641	-	_	
46-16	8641-8643	52	_	
46-17	8643-8644	”	_	
46-18	8645-8655	throughout	_	
46-19	8655-8656	)	_	
46-20	8657-8659	in	_	
46-21	8660-8663	the	_	
46-22	8664-8669	lower	_	
46-23	8670-8675	three	_	
46-24	8676-8680	rows	_	
46-25	8680-8681	,	_	
46-26	8682-8685	the	_	
46-27	8686-8695	threshold	_	
46-28	8696-8699	for	_	
46-29	8700-8712	significance	_	
46-30	8713-8715	of	_	
46-31	8716-8724	p-values	_	
46-32	8725-8728	was	_	
46-33	8729-8732	set	_	
46-34	8733-8735	at	_	
46-35	8736-8742	0.0016	_	
46-36	8743-8744	(	_	
46-37	8744-8748	0.05	_	
46-38	8748-8749	/	_	
46-39	8749-8751	31	_	
46-40	8751-8752	)	_	
46-41	8753-8758	using	_	
46-42	8759-8762	the	_	
46-43	8763-8773	Bonferroni	_	
46-44	8774-8784	correction	_	
46-45	8784-8785	.	_	

#Text=All statistical tests were performed with GraphPad Prism 6.0 for Windows version 6.07 (GraphPad Software, Inc., La Jolla, CA, USA).
47-1	8786-8789	All	_	
47-2	8790-8801	statistical	_	
47-3	8802-8807	tests	_	
47-4	8808-8812	were	_	
47-5	8813-8822	performed	_	
47-6	8823-8827	with	_	
47-7	8828-8836	GraphPad	_	
47-8	8837-8842	Prism	_	
47-9	8843-8846	6.0	_	
47-10	8847-8850	for	_	
47-11	8851-8858	Windows	_	
47-12	8859-8866	version	_	
47-13	8867-8871	6.07	_	
47-14	8872-8873	(	_	
47-15	8873-8881	GraphPad	_	
47-16	8882-8890	Software	_	
47-17	8890-8891	,	_	
47-18	8892-8895	Inc	_	
47-19	8895-8896	.	_	
47-20	8896-8897	,	_	
47-21	8898-8900	La	_	
47-22	8901-8906	Jolla	_	
47-23	8906-8907	,	_	
47-24	8908-8910	CA	_	
47-25	8910-8911	,	_	
47-26	8912-8915	USA	_	
47-27	8915-8916	)	_	
47-28	8916-8917	.	_	

#Text=Results
#Text=Task performance
#Text=The number of words generated during the task did not differ significantly among the three m-VFT sessions (first session: mean ± SD = 15.7 ± 3.5, second session: 15.8 ± 3.7, and third session: 16.8 ± 3.3; F [1.8, 35.0] = 1.3, p = 0.29).
48-1	8918-8925	Results	_	
48-2	8926-8930	Task	_	
48-3	8931-8942	performance	_	
48-4	8943-8946	The	_	
48-5	8947-8953	number	_	
48-6	8954-8956	of	_	
48-7	8957-8962	words	_	
48-8	8963-8972	generated	_	
48-9	8973-8979	during	_	
48-10	8980-8983	the	_	
48-11	8984-8988	task	_	
48-12	8989-8992	did	_	
48-13	8993-8996	not	_	
48-14	8997-9003	differ	_	
48-15	9004-9017	significantly	_	
48-16	9018-9023	among	_	
48-17	9024-9027	the	_	
48-18	9028-9033	three	_	
48-19	9034-9039	m-VFT	_	
48-20	9040-9048	sessions	_	
48-21	9049-9050	(	_	
48-22	9050-9055	first	_	
48-23	9056-9063	session	_	
48-24	9063-9064	:	_	
48-25	9065-9069	mean	_	
48-26	9070-9071	±	_	
48-27	9072-9074	SD	_	
48-28	9075-9076	=	_	
48-29	9077-9081	15.7	_	
48-30	9082-9083	±	_	
48-31	9084-9087	3.5	_	
48-32	9087-9088	,	_	
48-33	9089-9095	second	_	
48-34	9096-9103	session	_	
48-35	9103-9104	:	_	
48-36	9105-9109	15.8	_	
48-37	9110-9111	±	_	
48-38	9112-9115	3.7	_	
48-39	9115-9116	,	_	
48-40	9117-9120	and	_	
48-41	9121-9126	third	_	
48-42	9127-9134	session	_	
48-43	9134-9135	:	_	
48-44	9136-9140	16.8	_	
48-45	9141-9142	±	_	
48-46	9143-9146	3.3	_	
48-47	9146-9147	;	_	
48-48	9148-9149	F	_	
48-49	9150-9151	[	_	
48-50	9151-9154	1.8	_	
48-51	9154-9155	,	_	
48-52	9156-9160	35.0	_	
48-53	9160-9161	]	_	
48-54	9162-9163	=	_	
48-55	9164-9167	1.3	_	
48-56	9167-9168	,	_	
48-57	9169-9170	p	_	
48-58	9171-9172	=	_	
48-59	9173-9177	0.29	_	
48-60	9177-9178	)	_	
48-61	9178-9179	.	_	

#Text=NIRS data analysis
#Text=The m-VFT, especially the 1st session, revealed increased oxy-Hb signals during the task in all the NIRS channels analyzed in this study.
49-1	9180-9184	NIRS	_	
49-2	9185-9189	data	_	
49-3	9190-9198	analysis	_	
49-4	9199-9202	The	_	
49-5	9203-9208	m-VFT	_	
49-6	9208-9209	,	_	
49-7	9210-9220	especially	_	
49-8	9221-9224	the	_	
49-9	9225-9228	1st	_	
49-10	9229-9236	session	_	
49-11	9236-9237	,	_	
49-12	9238-9246	revealed	_	
49-13	9247-9256	increased	_	
49-14	9257-9263	oxy-Hb	_	
49-15	9264-9271	signals	_	
49-16	9272-9278	during	_	
49-17	9279-9282	the	_	
49-18	9283-9287	task	_	
49-19	9288-9290	in	_	
49-20	9291-9294	all	_	
49-21	9295-9298	the	_	
49-22	9299-9303	NIRS	_	
49-23	9304-9312	channels	_	
49-24	9313-9321	analyzed	_	
49-25	9322-9324	in	_	
49-26	9325-9329	this	_	
49-27	9330-9335	study	_	
49-28	9335-9336	.	_	

#Text=Within the 31 channels, those judged by ETG-4000 software to be probe errors throughout the three m-VFT sessions were excluded from the analysis.
50-1	9337-9343	Within	_	
50-2	9344-9347	the	_	
50-3	9348-9350	31	_	
50-4	9351-9359	channels	_	
50-5	9359-9360	,	_	
50-6	9361-9366	those	_	
50-7	9367-9373	judged	_	
50-8	9374-9376	by	_	
50-9	9377-9380	ETG	_	
50-10	9380-9381	-	_	
50-11	9381-9385	4000	_	
50-12	9386-9394	software	_	
50-13	9395-9397	to	_	
50-14	9398-9400	be	_	
50-15	9401-9406	probe	_	
50-16	9407-9413	errors	_	
50-17	9414-9424	throughout	_	
50-18	9425-9428	the	_	
50-19	9429-9434	three	_	
50-20	9435-9440	m-VFT	_	
50-21	9441-9449	sessions	_	
50-22	9450-9454	were	_	
50-23	9455-9463	excluded	_	
50-24	9464-9468	from	_	
50-25	9469-9472	the	_	
50-26	9473-9481	analysis	_	
50-27	9481-9482	.	_	

#Text=According to this criterion, ch42 was excluded in two subjects, and ch23, 26, 31, 32, 33, 37, and 51 were excluded in one subject.
51-1	9483-9492	According	_	
51-2	9493-9495	to	_	
51-3	9496-9500	this	_	
51-4	9501-9510	criterion	_	
51-5	9510-9511	,	_	
51-6	9512-9516	ch42	_	
51-7	9517-9520	was	_	
51-8	9521-9529	excluded	_	
51-9	9530-9532	in	_	
51-10	9533-9536	two	_	
51-11	9537-9545	subjects	_	
51-12	9545-9546	,	_	
51-13	9547-9550	and	_	
51-14	9551-9555	ch23	_	
51-15	9555-9556	,	_	
51-16	9557-9559	26	_	
51-17	9559-9560	,	_	
51-18	9561-9563	31	_	
51-19	9563-9564	,	_	
51-20	9565-9567	32	_	
51-21	9567-9568	,	_	
51-22	9569-9571	33	_	
51-23	9571-9572	,	_	
51-24	9573-9575	37	_	
51-25	9575-9576	,	_	
51-26	9577-9580	and	_	
51-27	9581-9583	51	_	
51-28	9584-9588	were	_	
51-29	9589-9597	excluded	_	
51-30	9598-9600	in	_	
51-31	9601-9604	one	_	
51-32	9605-9612	subject	_	
51-33	9612-9613	.	_	

#Text=In the repeated-measures ANOVA examining mean oxy-Hb signals during the task, significant differences were found on ch27 (F[DFn = 1.7, DFd = 31.7] = 9.0, p = 0.0014), ch28 (F[1.7, 31.5] = 9.7, p = 0.0010), ch29 (F[1.5, 28.7] = 9.9, p = 0.0013), and ch38 (F[1.9, 35.2] = 8.7, p = 0.0011; Figs 2 and 3A).
52-1	9614-9616	In	_	
52-2	9617-9620	the	_	
52-3	9621-9638	repeated-measures	_	
52-4	9639-9644	ANOVA	_	
52-5	9645-9654	examining	_	
52-6	9655-9659	mean	_	
52-7	9660-9666	oxy-Hb	_	
52-8	9667-9674	signals	_	
52-9	9675-9681	during	_	
52-10	9682-9685	the	_	
52-11	9686-9690	task	_	
52-12	9690-9691	,	_	
52-13	9692-9703	significant	_	
52-14	9704-9715	differences	_	
52-15	9716-9720	were	_	
52-16	9721-9726	found	_	
52-17	9727-9729	on	_	
52-18	9730-9734	ch27	_	
52-19	9735-9736	(	_	
52-20	9736-9737	F	_	
52-21	9737-9738	[	_	
52-22	9738-9741	DFn	_	
52-23	9742-9743	=	_	
52-24	9744-9747	1.7	_	
52-25	9747-9748	,	_	
52-26	9749-9752	DFd	_	
52-27	9753-9754	=	_	
52-28	9755-9759	31.7	_	
52-29	9759-9760	]	_	
52-30	9761-9762	=	_	
52-31	9763-9766	9.0	_	
52-32	9766-9767	,	_	
52-33	9768-9769	p	_	
52-34	9770-9771	=	_	
52-35	9772-9778	0.0014	_	
52-36	9778-9779	)	_	
52-37	9779-9780	,	_	
52-38	9781-9785	ch28	_	
52-39	9786-9787	(	_	
52-40	9787-9788	F	_	
52-41	9788-9789	[	_	
52-42	9789-9792	1.7	_	
52-43	9792-9793	,	_	
52-44	9794-9798	31.5	_	
52-45	9798-9799	]	_	
52-46	9800-9801	=	_	
52-47	9802-9805	9.7	_	
52-48	9805-9806	,	_	
52-49	9807-9808	p	_	
52-50	9809-9810	=	_	
52-51	9811-9817	0.0010	_	
52-52	9817-9818	)	_	
52-53	9818-9819	,	_	
52-54	9820-9824	ch29	_	
52-55	9825-9826	(	_	
52-56	9826-9827	F	_	
52-57	9827-9828	[	_	
52-58	9828-9831	1.5	_	
52-59	9831-9832	,	_	
52-60	9833-9837	28.7	_	
52-61	9837-9838	]	_	
52-62	9839-9840	=	_	
52-63	9841-9844	9.9	_	
52-64	9844-9845	,	_	
52-65	9846-9847	p	_	
52-66	9848-9849	=	_	
52-67	9850-9856	0.0013	_	
52-68	9856-9857	)	_	
52-69	9857-9858	,	_	
52-70	9859-9862	and	_	
52-71	9863-9867	ch38	_	
52-72	9868-9869	(	_	
52-73	9869-9870	F	_	
52-74	9870-9871	[	_	
52-75	9871-9874	1.9	_	
52-76	9874-9875	,	_	
52-77	9876-9880	35.2	_	
52-78	9880-9881	]	_	
52-79	9882-9883	=	_	
52-80	9884-9887	8.7	_	
52-81	9887-9888	,	_	
52-82	9889-9890	p	_	
52-83	9891-9892	=	_	
52-84	9893-9899	0.0011	_	
52-85	9899-9900	;	_	
52-86	9901-9905	Figs	_	
52-87	9906-9907	2	_	
52-88	9908-9911	and	_	
52-89	9912-9914	3A	_	
52-90	9914-9915	)	_	
52-91	9915-9916	.	_	

#Text=All p-values in the repeated-measures ANOVA for the remaining channels were above 0.0016.
53-1	9917-9920	All	_	
53-2	9921-9929	p-values	_	
53-3	9930-9932	in	_	
53-4	9933-9936	the	_	
53-5	9937-9954	repeated-measures	_	
53-6	9955-9960	ANOVA	_	
53-7	9961-9964	for	_	
53-8	9965-9968	the	_	
53-9	9969-9978	remaining	_	
53-10	9979-9987	channels	_	
53-11	9988-9992	were	_	
53-12	9993-9998	above	_	
53-13	9999-10005	0.0016	_	
53-14	10005-10006	.	_	

#Text=Dunnett’s post-hoc multiple comparison test of the four channels showed that mean oxy-Hb signals during the task were significantly decreased in the third compared with the first session on ch28 (first vs second session: p = 0.0206; first vs third session: p = 0.0008; Fig 3B).
54-1	10007-10014	Dunnett	_	
54-2	10014-10015	’	_	
54-3	10015-10016	s	_	
54-4	10017-10025	post-hoc	_	
54-5	10026-10034	multiple	_	
54-6	10035-10045	comparison	_	
54-7	10046-10050	test	_	
54-8	10051-10053	of	_	
54-9	10054-10057	the	_	
54-10	10058-10062	four	_	
54-11	10063-10071	channels	_	
54-12	10072-10078	showed	_	
54-13	10079-10083	that	_	
54-14	10084-10088	mean	_	
54-15	10089-10095	oxy-Hb	_	
54-16	10096-10103	signals	_	
54-17	10104-10110	during	_	
54-18	10111-10114	the	_	
54-19	10115-10119	task	_	
54-20	10120-10124	were	_	
54-21	10125-10138	significantly	_	
54-22	10139-10148	decreased	_	
54-23	10149-10151	in	_	
54-24	10152-10155	the	_	
54-25	10156-10161	third	_	
54-26	10162-10170	compared	_	
54-27	10171-10175	with	_	
54-28	10176-10179	the	_	
54-29	10180-10185	first	_	
54-30	10186-10193	session	_	
54-31	10194-10196	on	_	
54-32	10197-10201	ch28	_	
54-33	10202-10203	(	_	
54-34	10203-10208	first	_	
54-35	10209-10211	vs	_	
54-36	10212-10218	second	_	
54-37	10219-10226	session	_	
54-38	10226-10227	:	_	
54-39	10228-10229	p	_	
54-40	10230-10231	=	_	
54-41	10232-10238	0.0206	_	
54-42	10238-10239	;	_	
54-43	10240-10245	first	_	
54-44	10246-10248	vs	_	
54-45	10249-10254	third	_	
54-46	10255-10262	session	_	
54-47	10262-10263	:	_	
54-48	10264-10265	p	_	
54-49	10266-10267	=	_	
54-50	10268-10274	0.0008	_	
54-51	10274-10275	;	_	
54-52	10276-10279	Fig	_	
54-53	10280-10282	3B	_	
54-54	10282-10283	)	_	
54-55	10283-10284	.	_	

#Text=No significant differences in mean oxy-Hb signals during the task were observed on ch27 (first vs second session: p = 0.0353; first vs third session: p = 0.0035), ch29 (first vs second session: p = 0.0073; first vs third session: p = 0.0046), or ch38 (first vs second session: p = 0.0612; first vs third session: p = 0.0027).
55-1	10285-10287	No	_	
55-2	10288-10299	significant	_	
55-3	10300-10311	differences	_	
55-4	10312-10314	in	_	
55-5	10315-10319	mean	_	
55-6	10320-10326	oxy-Hb	_	
55-7	10327-10334	signals	_	
55-8	10335-10341	during	_	
55-9	10342-10345	the	_	
55-10	10346-10350	task	_	
55-11	10351-10355	were	_	
55-12	10356-10364	observed	_	
55-13	10365-10367	on	_	
55-14	10368-10372	ch27	_	
55-15	10373-10374	(	_	
55-16	10374-10379	first	_	
55-17	10380-10382	vs	_	
55-18	10383-10389	second	_	
55-19	10390-10397	session	_	
55-20	10397-10398	:	_	
55-21	10399-10400	p	_	
55-22	10401-10402	=	_	
55-23	10403-10409	0.0353	_	
55-24	10409-10410	;	_	
55-25	10411-10416	first	_	
55-26	10417-10419	vs	_	
55-27	10420-10425	third	_	
55-28	10426-10433	session	_	
55-29	10433-10434	:	_	
55-30	10435-10436	p	_	
55-31	10437-10438	=	_	
55-32	10439-10445	0.0035	_	
55-33	10445-10446	)	_	
55-34	10446-10447	,	_	
55-35	10448-10452	ch29	_	
55-36	10453-10454	(	_	
55-37	10454-10459	first	_	
55-38	10460-10462	vs	_	
55-39	10463-10469	second	_	
55-40	10470-10477	session	_	
55-41	10477-10478	:	_	
55-42	10479-10480	p	_	
55-43	10481-10482	=	_	
55-44	10483-10489	0.0073	_	
55-45	10489-10490	;	_	
55-46	10491-10496	first	_	
55-47	10497-10499	vs	_	
55-48	10500-10505	third	_	
55-49	10506-10513	session	_	
55-50	10513-10514	:	_	
55-51	10515-10516	p	_	
55-52	10517-10518	=	_	
55-53	10519-10525	0.0046	_	
55-54	10525-10526	)	_	
55-55	10526-10527	,	_	
55-56	10528-10530	or	_	
55-57	10531-10535	ch38	_	
55-58	10536-10537	(	_	
55-59	10537-10542	first	_	
55-60	10543-10545	vs	_	
55-61	10546-10552	second	_	
55-62	10553-10560	session	_	
55-63	10560-10561	:	_	
55-64	10562-10563	p	_	
55-65	10564-10565	=	_	
55-66	10566-10572	0.0612	_	
55-67	10572-10573	;	_	
55-68	10574-10579	first	_	
55-69	10580-10582	vs	_	
55-70	10583-10588	third	_	
55-71	10589-10596	session	_	
55-72	10596-10597	:	_	
55-73	10598-10599	p	_	
55-74	10600-10601	=	_	
55-75	10602-10608	0.0027	_	
55-76	10608-10609	)	_	
55-77	10609-10610	.	_	

#Text=Grand averages of waveforms of oxy-Hb signal changes across all subjects in three m-VFT sessions (black line: First session, blue line: Second session, and red line: Third session).
#Text=† represents p < 0.0016 in ANOVA. * represents p < 0.0016 in ANOVA with post-hoc test (first vs third session).
56-1	10611-10616	Grand	_	
56-2	10617-10625	averages	_	
56-3	10626-10628	of	_	
56-4	10629-10638	waveforms	_	
56-5	10639-10641	of	_	
56-6	10642-10648	oxy-Hb	_	
56-7	10649-10655	signal	_	
56-8	10656-10663	changes	_	
56-9	10664-10670	across	_	
56-10	10671-10674	all	_	
56-11	10675-10683	subjects	_	
56-12	10684-10686	in	_	
56-13	10687-10692	three	_	
56-14	10693-10698	m-VFT	_	
56-15	10699-10707	sessions	_	
56-16	10708-10709	(	_	
56-17	10709-10714	black	_	
56-18	10715-10719	line	_	
56-19	10719-10720	:	_	
56-20	10721-10726	First	_	
56-21	10727-10734	session	_	
56-22	10734-10735	,	_	
56-23	10736-10740	blue	_	
56-24	10741-10745	line	_	
56-25	10745-10746	:	_	
56-26	10747-10753	Second	_	
56-27	10754-10761	session	_	
56-28	10761-10762	,	_	
56-29	10763-10766	and	_	
56-30	10767-10770	red	_	
56-31	10771-10775	line	_	
56-32	10775-10776	:	_	
56-33	10777-10782	Third	_	
56-34	10783-10790	session	_	
56-35	10790-10791	)	_	
56-36	10791-10792	.	_	
56-37	10793-10794	†	_	
56-38	10795-10805	represents	_	
56-39	10806-10807	p	_	
56-40	10808-10809	<	_	
56-41	10810-10816	0.0016	_	
56-42	10817-10819	in	_	
56-43	10820-10825	ANOVA	_	
56-44	10825-10826	.	_	
56-45	10827-10828	*	_	
56-46	10829-10839	represents	_	
56-47	10840-10841	p	_	
56-48	10842-10843	<	_	
56-49	10844-10850	0.0016	_	
56-50	10851-10853	in	_	
56-51	10854-10859	ANOVA	_	
56-52	10860-10864	with	_	
56-53	10865-10873	post-hoc	_	
56-54	10874-10878	test	_	
56-55	10879-10880	(	_	
56-56	10880-10885	first	_	
56-57	10886-10888	vs	_	
56-58	10889-10894	third	_	
56-59	10895-10902	session	_	
56-60	10902-10903	)	_	
56-61	10903-10904	.	_	

#Text=Bonferroni-corrected α-level was 0.0016 (0.05/31).
57-1	10905-10925	Bonferroni-corrected	_	
57-2	10926-10933	α-level	_	
57-3	10934-10937	was	_	
57-4	10938-10944	0.0016	_	
57-5	10945-10946	(	_	
57-6	10946-10950	0.05	_	
57-7	10950-10951	/	_	
57-8	10951-10953	31	_	
57-9	10953-10954	)	_	
57-10	10954-10955	.	_	

#Text=(a) Location of channels where task-induced activation was significantly affected by repetition of m-VFT (highlighted in yellow).
58-1	10956-10957	(	_	
58-2	10957-10958	a	_	
58-3	10958-10959	)	_	
58-4	10960-10968	Location	_	
58-5	10969-10971	of	_	
58-6	10972-10980	channels	_	
58-7	10981-10986	where	_	
58-8	10987-10999	task-induced	_	
58-9	11000-11010	activation	_	
58-10	11011-11014	was	_	
58-11	11015-11028	significantly	_	
58-12	11029-11037	affected	_	
58-13	11038-11040	by	_	
58-14	11041-11051	repetition	_	
58-15	11052-11054	of	_	
58-16	11055-11060	m-VFT	_	
58-17	11061-11062	(	_	
58-18	11062-11073	highlighted	_	
58-19	11074-11076	in	_	
58-20	11077-11083	yellow	_	
58-21	11083-11084	)	_	
58-22	11084-11085	.	_	

#Text=(b) Mean oxy-Hb signals during the task in three m-VFT sessions on ch28.
59-1	11086-11087	(	_	
59-2	11087-11088	b	_	
59-3	11088-11089	)	_	
59-4	11090-11094	Mean	_	
59-5	11095-11101	oxy-Hb	_	
59-6	11102-11109	signals	_	
59-7	11110-11116	during	_	
59-8	11117-11120	the	_	
59-9	11121-11125	task	_	
59-10	11126-11128	in	_	
59-11	11129-11134	three	_	
59-12	11135-11140	m-VFT	_	
59-13	11141-11149	sessions	_	
59-14	11150-11152	on	_	
59-15	11153-11157	ch28	_	
59-16	11157-11158	.	_	

#Text=Significant attenuation of the activation was detected between first and third sessions on this channel.
60-1	11159-11170	Significant	_	
60-2	11171-11182	attenuation	_	
60-3	11183-11185	of	_	
60-4	11186-11189	the	_	
60-5	11190-11200	activation	_	
60-6	11201-11204	was	_	
60-7	11205-11213	detected	_	
60-8	11214-11221	between	_	
60-9	11222-11227	first	_	
60-10	11228-11231	and	_	
60-11	11232-11237	third	_	
60-12	11238-11246	sessions	_	
60-13	11247-11249	on	_	
60-14	11250-11254	this	_	
60-15	11255-11262	channel	_	
60-16	11262-11263	.	_	

#Text=Please refer to S1 Table. for the details of analyzed data.
61-1	11264-11270	Please	_	
61-2	11271-11276	refer	_	
61-3	11277-11279	to	_	
61-4	11280-11282	S1	_	
61-5	11283-11288	Table	_	
61-6	11288-11289	.	_	
61-7	11290-11293	for	_	
61-8	11294-11297	the	_	
61-9	11298-11305	details	_	
61-10	11306-11308	of	_	
61-11	11309-11317	analyzed	_	
61-12	11318-11322	data	_	
61-13	11322-11323	.	_	

#Text=Discussion
#Text=The present study was the first NIRS study, to our knowledge, to show how phonemic VFT-induced regional brain activation was changed during repetitive VFTs.
62-1	11324-11334	Discussion	_	
62-2	11335-11338	The	_	
62-3	11339-11346	present	_	
62-4	11347-11352	study	_	
62-5	11353-11356	was	_	
62-6	11357-11360	the	_	
62-7	11361-11366	first	_	
62-8	11367-11371	NIRS	_	
62-9	11372-11377	study	_	
62-10	11377-11378	,	_	
62-11	11379-11381	to	_	
62-12	11382-11385	our	_	
62-13	11386-11395	knowledge	_	
62-14	11395-11396	,	_	
62-15	11397-11399	to	_	
62-16	11400-11404	show	_	
62-17	11405-11408	how	_	
62-18	11409-11417	phonemic	_	
62-19	11418-11429	VFT-induced	_	
62-20	11430-11438	regional	_	
62-21	11439-11444	brain	_	
62-22	11445-11455	activation	_	
62-23	11456-11459	was	_	
62-24	11460-11467	changed	_	
62-25	11468-11474	during	_	
62-26	11475-11485	repetitive	_	
62-27	11486-11490	VFTs	_	
62-28	11490-11491	.	_	

#Text=Without obvious task performance change, which ensures the consistent commitment of subjects to the task, hemodynamic activation was significantly attenuated by repeating the m-VFT on four channels: ch27, 28, 29, and 38.
63-1	11492-11499	Without	_	
63-2	11500-11507	obvious	_	
63-3	11508-11512	task	_	
63-4	11513-11524	performance	_	
63-5	11525-11531	change	_	
63-6	11531-11532	,	_	
63-7	11533-11538	which	_	
63-8	11539-11546	ensures	_	
63-9	11547-11550	the	_	
63-10	11551-11561	consistent	_	
63-11	11562-11572	commitment	_	
63-12	11573-11575	of	_	
63-13	11576-11584	subjects	_	
63-14	11585-11587	to	_	
63-15	11588-11591	the	_	
63-16	11592-11596	task	_	
63-17	11596-11597	,	_	
63-18	11598-11609	hemodynamic	_	
63-19	11610-11620	activation	_	
63-20	11621-11624	was	_	
63-21	11625-11638	significantly	_	
63-22	11639-11649	attenuated	_	
63-23	11650-11652	by	_	
63-24	11653-11662	repeating	_	
63-25	11663-11666	the	_	
63-26	11667-11672	m-VFT	_	
63-27	11673-11675	on	_	
63-28	11676-11680	four	_	
63-29	11681-11689	channels	_	
63-30	11689-11690	:	_	
63-31	11691-11695	ch27	_	
63-32	11695-11696	,	_	
63-33	11697-11699	28	_	
63-34	11699-11700	,	_	
63-35	11701-11703	29	_	
63-36	11703-11704	,	_	
63-37	11705-11708	and	_	
63-38	11709-11711	38	_	
63-39	11711-11712	.	_	

#Text=These four channels were located in the left PFC.
64-1	11713-11718	These	_	
64-2	11719-11723	four	_	
64-3	11724-11732	channels	_	
64-4	11733-11737	were	_	
64-5	11738-11745	located	_	
64-6	11746-11748	in	_	
64-7	11749-11752	the	_	
64-8	11753-11757	left	_	
64-9	11758-11761	PFC	_	
64-10	11761-11762	.	_	

#Text=In contrast; none of the channels located in the right hemisphere reached statistical significance.
65-1	11763-11765	In	_	
65-2	11766-11774	contrast	_	
65-3	11774-11775	;	_	
65-4	11776-11780	none	_	
65-5	11781-11783	of	_	
65-6	11784-11787	the	_	
65-7	11788-11796	channels	_	
65-8	11797-11804	located	_	
65-9	11805-11807	in	_	
65-10	11808-11811	the	_	
65-11	11812-11817	right	_	
65-12	11818-11828	hemisphere	_	
65-13	11829-11836	reached	_	
65-14	11837-11848	statistical	_	
65-15	11849-11861	significance	_	
65-16	11861-11862	.	_	

#Text=The attenuation of m-VFT-induced activation was pronounced on ch28, which is annotated in the left dorsolateral PFC (DLPFC) according to a virtual registration of the NIRS channels.
66-1	11863-11866	The	_	
66-2	11867-11878	attenuation	_	
66-3	11879-11881	of	_	
66-4	11882-11895	m-VFT-induced	_	
66-5	11896-11906	activation	_	
66-6	11907-11910	was	_	
66-7	11911-11921	pronounced	_	
66-8	11922-11924	on	_	
66-9	11925-11929	ch28	_	
66-10	11929-11930	,	_	
66-11	11931-11936	which	_	
66-12	11937-11939	is	_	
66-13	11940-11949	annotated	_	
66-14	11950-11952	in	_	
66-15	11953-11956	the	_	
66-16	11957-11961	left	_	
66-17	11962-11974	dorsolateral	_	
66-18	11975-11978	PFC	_	
66-19	11979-11980	(	_	
66-20	11980-11985	DLPFC	_	
66-21	11985-11986	)	_	
66-22	11987-11996	according	_	
66-23	11997-11999	to	_	
66-24	12000-12001	a	_	
66-25	12002-12009	virtual	_	
66-26	12010-12022	registration	_	
66-27	12023-12025	of	_	
66-28	12026-12029	the	_	
66-29	12030-12034	NIRS	_	
66-30	12035-12043	channels	_	
66-31	12043-12044	.	_	

#Text=These findings demonstrate that repetition of the m-VFT attenuated the task-induced activation in the left PFC, where the attenuation was presumably emphasized in the left DLPFC.
67-1	12045-12050	These	_	
67-2	12051-12059	findings	_	
67-3	12060-12071	demonstrate	_	
67-4	12072-12076	that	_	
67-5	12077-12087	repetition	_	
67-6	12088-12090	of	_	
67-7	12091-12094	the	_	
67-8	12095-12100	m-VFT	_	
67-9	12101-12111	attenuated	_	
67-10	12112-12115	the	_	
67-11	12116-12128	task-induced	_	
67-12	12129-12139	activation	_	
67-13	12140-12142	in	_	
67-14	12143-12146	the	_	
67-15	12147-12151	left	_	
67-16	12152-12155	PFC	_	
67-17	12155-12156	,	_	
67-18	12157-12162	where	_	
67-19	12163-12166	the	_	
67-20	12167-12178	attenuation	_	
67-21	12179-12182	was	_	
67-22	12183-12193	presumably	_	
67-23	12194-12204	emphasized	_	
67-24	12205-12207	in	_	
67-25	12208-12211	the	_	
67-26	12212-12216	left	_	
67-27	12217-12222	DLPFC	_	
67-28	12222-12223	.	_	

#Text=The left PFC is a central region for verbal processing.
68-1	12224-12227	The	_	
68-2	12228-12232	left	_	
68-3	12233-12236	PFC	_	
68-4	12237-12239	is	_	
68-5	12240-12241	a	_	
68-6	12242-12249	central	_	
68-7	12250-12256	region	_	
68-8	12257-12260	for	_	
68-9	12261-12267	verbal	_	
68-10	12268-12278	processing	_	
68-11	12278-12279	.	_	

#Text=Within the PFC, working memory postulates a crucial role in the dorsolateral portion.
69-1	12280-12286	Within	_	
69-2	12287-12290	the	_	
69-3	12291-12294	PFC	_	
69-4	12294-12295	,	_	
69-5	12296-12303	working	_	
69-6	12304-12310	memory	_	
69-7	12311-12321	postulates	_	
69-8	12322-12323	a	_	
69-9	12324-12331	crucial	_	
69-10	12332-12336	role	_	
69-11	12337-12339	in	_	
69-12	12340-12343	the	_	
69-13	12344-12356	dorsolateral	_	
69-14	12357-12364	portion	_	
69-15	12364-12365	.	_	

#Text=Consistent with this line of evidence, a PET study showed that the left DLPFC mediates the manipulation of verbal working memory.
70-1	12366-12376	Consistent	_	
70-2	12377-12381	with	_	
70-3	12382-12386	this	_	
70-4	12387-12391	line	_	
70-5	12392-12394	of	_	
70-6	12395-12403	evidence	_	
70-7	12403-12404	,	_	
70-8	12405-12406	a	_	
70-9	12407-12410	PET	_	
70-10	12411-12416	study	_	
70-11	12417-12423	showed	_	
70-12	12424-12428	that	_	
70-13	12429-12432	the	_	
70-14	12433-12437	left	_	
70-15	12438-12443	DLPFC	_	
70-16	12444-12452	mediates	_	
70-17	12453-12456	the	_	
70-18	12457-12469	manipulation	_	
70-19	12470-12472	of	_	
70-20	12473-12479	verbal	_	
70-21	12480-12487	working	_	
70-22	12488-12494	memory	_	
70-23	12494-12495	.	_	

#Text=Several fMRI studies reported that working memory tasks induced less activation after repetition of the task, even without obvious task performance change.
71-1	12496-12503	Several	_	
71-2	12504-12508	fMRI	_	
71-3	12509-12516	studies	_	
71-4	12517-12525	reported	_	
71-5	12526-12530	that	_	
71-6	12531-12538	working	_	
71-7	12539-12545	memory	_	
71-8	12546-12551	tasks	_	
71-9	12552-12559	induced	_	
71-10	12560-12564	less	_	
71-11	12565-12575	activation	_	
71-12	12576-12581	after	_	
71-13	12582-12592	repetition	_	
71-14	12593-12595	of	_	
71-15	12596-12599	the	_	
71-16	12600-12604	task	_	
71-17	12604-12605	,	_	
71-18	12606-12610	even	_	
71-19	12611-12618	without	_	
71-20	12619-12626	obvious	_	
71-21	12627-12631	task	_	
71-22	12632-12643	performance	_	
71-23	12644-12650	change	_	
71-24	12650-12651	.	_	

#Text=One mechanism underlying this phenomenon is believed to be improved neural efficiency of task processing.
72-1	12652-12655	One	_	
72-2	12656-12665	mechanism	_	
72-3	12666-12676	underlying	_	
72-4	12677-12681	this	_	
72-5	12682-12692	phenomenon	_	
72-6	12693-12695	is	_	
72-7	12696-12704	believed	_	
72-8	12705-12707	to	_	
72-9	12708-12710	be	_	
72-10	12711-12719	improved	_	
72-11	12720-12726	neural	_	
72-12	12727-12737	efficiency	_	
72-13	12738-12740	of	_	
72-14	12741-12745	task	_	
72-15	12746-12756	processing	_	
72-16	12756-12757	.	_	

#Text=Because the automated processing induced by repeating a working memory task results in a reduced demand on the working memory load, it also reduces the activity in the task-related brain areas such as left DLPFC.
73-1	12758-12765	Because	_	
73-2	12766-12769	the	_	
73-3	12770-12779	automated	_	
73-4	12780-12790	processing	_	
73-5	12791-12798	induced	_	
73-6	12799-12801	by	_	
73-7	12802-12811	repeating	_	
73-8	12812-12813	a	_	
73-9	12814-12821	working	_	
73-10	12822-12828	memory	_	
73-11	12829-12833	task	_	
73-12	12834-12841	results	_	
73-13	12842-12844	in	_	
73-14	12845-12846	a	_	
73-15	12847-12854	reduced	_	
73-16	12855-12861	demand	_	
73-17	12862-12864	on	_	
73-18	12865-12868	the	_	
73-19	12869-12876	working	_	
73-20	12877-12883	memory	_	
73-21	12884-12888	load	_	
73-22	12888-12889	,	_	
73-23	12890-12892	it	_	
73-24	12893-12897	also	_	
73-25	12898-12905	reduces	_	
73-26	12906-12909	the	_	
73-27	12910-12918	activity	_	
73-28	12919-12921	in	_	
73-29	12922-12925	the	_	
73-30	12926-12938	task-related	_	
73-31	12939-12944	brain	_	
73-32	12945-12950	areas	_	
73-33	12951-12955	such	_	
73-34	12956-12958	as	_	
73-35	12959-12963	left	_	
73-36	12964-12969	DLPFC	_	
73-37	12969-12970	.	_	

#Text=Combined with the evidence that working memory is engaged in the VFT, these lines of evidence suggest that our results—that is, the attenuated activation around the left DLPFC without task performance change—are due to an improved neural efficiency to manipulate the VFT.
74-1	12971-12979	Combined	_	
74-2	12980-12984	with	_	
74-3	12985-12988	the	_	
74-4	12989-12997	evidence	_	
74-5	12998-13002	that	_	
74-6	13003-13010	working	_	
74-7	13011-13017	memory	_	
74-8	13018-13020	is	_	
74-9	13021-13028	engaged	_	
74-10	13029-13031	in	_	
74-11	13032-13035	the	_	
74-12	13036-13039	VFT	_	
74-13	13039-13040	,	_	
74-14	13041-13046	these	_	
74-15	13047-13052	lines	_	
74-16	13053-13055	of	_	
74-17	13056-13064	evidence	_	
74-18	13065-13072	suggest	_	
74-19	13073-13077	that	_	
74-20	13078-13081	our	_	
74-21	13082-13094	results—that	_	
74-22	13095-13097	is	_	
74-23	13097-13098	,	_	
74-24	13099-13102	the	_	
74-25	13103-13113	attenuated	_	
74-26	13114-13124	activation	_	
74-27	13125-13131	around	_	
74-28	13132-13135	the	_	
74-29	13136-13140	left	_	
74-30	13141-13146	DLPFC	_	
74-31	13147-13154	without	_	
74-32	13155-13159	task	_	
74-33	13160-13171	performance	_	
74-34	13172-13182	change—are	_	
74-35	13183-13186	due	_	
74-36	13187-13189	to	_	
74-37	13190-13192	an	_	
74-38	13193-13201	improved	_	
74-39	13202-13208	neural	_	
74-40	13209-13219	efficiency	_	
74-41	13220-13222	to	_	
74-42	13223-13233	manipulate	_	
74-43	13234-13237	the	_	
74-44	13238-13241	VFT	_	
74-45	13241-13242	.	_	

#Text=Nonetheless, some other possibilities cannot be excluded, which may potentially explain the decrease of the oxy-Hb found in our study, e.g., mediation of some cognitive process may be implemented only in the initial phase of task learning or over-activation amplified in the initial phase of task may be optimized during task repetition.
75-1	13243-13254	Nonetheless	_	
75-2	13254-13255	,	_	
75-3	13256-13260	some	_	
75-4	13261-13266	other	_	
75-5	13267-13280	possibilities	_	
75-6	13281-13287	cannot	_	
75-7	13288-13290	be	_	
75-8	13291-13299	excluded	_	
75-9	13299-13300	,	_	
75-10	13301-13306	which	_	
75-11	13307-13310	may	_	
75-12	13311-13322	potentially	_	
75-13	13323-13330	explain	_	
75-14	13331-13334	the	_	
75-15	13335-13343	decrease	_	
75-16	13344-13346	of	_	
75-17	13347-13350	the	_	
75-18	13351-13357	oxy-Hb	_	
75-19	13358-13363	found	_	
75-20	13364-13366	in	_	
75-21	13367-13370	our	_	
75-22	13371-13376	study	_	
75-23	13376-13377	,	_	
75-24	13378-13381	e.g	_	
75-25	13381-13382	.	_	
75-26	13382-13383	,	_	
75-27	13384-13393	mediation	_	
75-28	13394-13396	of	_	
75-29	13397-13401	some	_	
75-30	13402-13411	cognitive	_	
75-31	13412-13419	process	_	
75-32	13420-13423	may	_	
75-33	13424-13426	be	_	
75-34	13427-13438	implemented	_	
75-35	13439-13443	only	_	
75-36	13444-13446	in	_	
75-37	13447-13450	the	_	
75-38	13451-13458	initial	_	
75-39	13459-13464	phase	_	
75-40	13465-13467	of	_	
75-41	13468-13472	task	_	
75-42	13473-13481	learning	_	
75-43	13482-13484	or	_	
75-44	13485-13500	over-activation	_	
75-45	13501-13510	amplified	_	
75-46	13511-13513	in	_	
75-47	13514-13517	the	_	
75-48	13518-13525	initial	_	
75-49	13526-13531	phase	_	
75-50	13532-13534	of	_	
75-51	13535-13539	task	_	
75-52	13540-13543	may	_	
75-53	13544-13546	be	_	
75-54	13547-13556	optimized	_	
75-55	13557-13563	during	_	
75-56	13564-13568	task	_	
75-57	13569-13579	repetition	_	
75-58	13579-13580	.	_	

#Text=A number of fMRI studies have shown that the left PFC is potently activated by the phonemic VFT, and a fMRI study reported that a phonemic VFT that contained switching of the designated syllables exhibited left PFC hypoactivation in depressed patients compared with controls.
76-1	13581-13582	A	_	
76-2	13583-13589	number	_	
76-3	13590-13592	of	_	
76-4	13593-13597	fMRI	_	
76-5	13598-13605	studies	_	
76-6	13606-13610	have	_	
76-7	13611-13616	shown	_	
76-8	13617-13621	that	_	
76-9	13622-13625	the	_	
76-10	13626-13630	left	_	
76-11	13631-13634	PFC	_	
76-12	13635-13637	is	_	
76-13	13638-13646	potently	_	
76-14	13647-13656	activated	_	
76-15	13657-13659	by	_	
76-16	13660-13663	the	_	
76-17	13664-13672	phonemic	_	
76-18	13673-13676	VFT	_	
76-19	13676-13677	,	_	
76-20	13678-13681	and	_	
76-21	13682-13683	a	_	
76-22	13684-13688	fMRI	_	
76-23	13689-13694	study	_	
76-24	13695-13703	reported	_	
76-25	13704-13708	that	_	
76-26	13709-13710	a	_	
76-27	13711-13719	phonemic	_	
76-28	13720-13723	VFT	_	
76-29	13724-13728	that	_	
76-30	13729-13738	contained	_	
76-31	13739-13748	switching	_	
76-32	13749-13751	of	_	
76-33	13752-13755	the	_	
76-34	13756-13766	designated	_	
76-35	13767-13776	syllables	_	
76-36	13777-13786	exhibited	_	
76-37	13787-13791	left	_	
76-38	13792-13795	PFC	_	
76-39	13796-13810	hypoactivation	_	
76-40	13811-13813	in	_	
76-41	13814-13823	depressed	_	
76-42	13824-13832	patients	_	
76-43	13833-13841	compared	_	
76-44	13842-13846	with	_	
76-45	13847-13855	controls	_	
76-46	13855-13856	.	_	

#Text=While NIRS studies show bilateral fronto-temporal activation during the m-VFT in healthy controls, depressed patients are reported to have a weaker activation in the left PFC during the first half of the task.
77-1	13857-13862	While	_	
77-2	13863-13867	NIRS	_	
77-3	13868-13875	studies	_	
77-4	13876-13880	show	_	
77-5	13881-13890	bilateral	_	
77-6	13891-13906	fronto-temporal	_	
77-7	13907-13917	activation	_	
77-8	13918-13924	during	_	
77-9	13925-13928	the	_	
77-10	13929-13934	m-VFT	_	
77-11	13935-13937	in	_	
77-12	13938-13945	healthy	_	
77-13	13946-13954	controls	_	
77-14	13954-13955	,	_	
77-15	13956-13965	depressed	_	
77-16	13966-13974	patients	_	
77-17	13975-13978	are	_	
77-18	13979-13987	reported	_	
77-19	13988-13990	to	_	
77-20	13991-13995	have	_	
77-21	13996-13997	a	_	
77-22	13998-14004	weaker	_	
77-23	14005-14015	activation	_	
77-24	14016-14018	in	_	
77-25	14019-14022	the	_	
77-26	14023-14027	left	_	
77-27	14028-14031	PFC	_	
77-28	14032-14038	during	_	
77-29	14039-14042	the	_	
77-30	14043-14048	first	_	
77-31	14049-14053	half	_	
77-32	14054-14056	of	_	
77-33	14057-14060	the	_	
77-34	14061-14065	task	_	
77-35	14065-14066	.	_	

#Text=Because the laterality change was found in the VFT with the switching of the designated syllables in these studies, Klumpp et al. hypothesized that VFTs that require more switching among phonemes may be more sensitive to left frontal lobe deficits than those with less switching.
78-1	14067-14074	Because	_	
78-2	14075-14078	the	_	
78-3	14079-14089	laterality	_	
78-4	14090-14096	change	_	
78-5	14097-14100	was	_	
78-6	14101-14106	found	_	
78-7	14107-14109	in	_	
78-8	14110-14113	the	_	
78-9	14114-14117	VFT	_	
78-10	14118-14122	with	_	
78-11	14123-14126	the	_	
78-12	14127-14136	switching	_	
78-13	14137-14139	of	_	
78-14	14140-14143	the	_	
78-15	14144-14154	designated	_	
78-16	14155-14164	syllables	_	
78-17	14165-14167	in	_	
78-18	14168-14173	these	_	
78-19	14174-14181	studies	_	
78-20	14181-14182	,	_	
78-21	14183-14189	Klumpp	_	
78-22	14190-14192	et	_	
78-23	14193-14195	al	_	
78-24	14195-14196	.	_	
78-25	14197-14209	hypothesized	_	
78-26	14210-14214	that	_	
78-27	14215-14219	VFTs	_	
78-28	14220-14224	that	_	
78-29	14225-14232	require	_	
78-30	14233-14237	more	_	
78-31	14238-14247	switching	_	
78-32	14248-14253	among	_	
78-33	14254-14262	phonemes	_	
78-34	14263-14266	may	_	
78-35	14267-14269	be	_	
78-36	14270-14274	more	_	
78-37	14275-14284	sensitive	_	
78-38	14285-14287	to	_	
78-39	14288-14292	left	_	
78-40	14293-14300	frontal	_	
78-41	14301-14305	lobe	_	
78-42	14306-14314	deficits	_	
78-43	14315-14319	than	_	
78-44	14320-14325	those	_	
78-45	14326-14330	with	_	
78-46	14331-14335	less	_	
78-47	14336-14345	switching	_	
78-48	14345-14346	.	_	

#Text=Our results support this hypothesis from the viewpoint of normal engagement of the left PFC in manipulating the VFT.
79-1	14347-14350	Our	_	
79-2	14351-14358	results	_	
79-3	14359-14366	support	_	
79-4	14367-14371	this	_	
79-5	14372-14382	hypothesis	_	
79-6	14383-14387	from	_	
79-7	14388-14391	the	_	
79-8	14392-14401	viewpoint	_	
79-9	14402-14404	of	_	
79-10	14405-14411	normal	_	
79-11	14412-14422	engagement	_	
79-12	14423-14425	of	_	
79-13	14426-14429	the	_	
79-14	14430-14434	left	_	
79-15	14435-14438	PFC	_	
79-16	14439-14441	in	_	
79-17	14442-14454	manipulating	_	
79-18	14455-14458	the	_	
79-19	14459-14462	VFT	_	
79-20	14462-14463	.	_	

#Text=Further, our results could guide further development of the current VFT to focus more on left PFC dysfunction.
80-1	14464-14471	Further	_	
80-2	14471-14472	,	_	
80-3	14473-14476	our	_	
80-4	14477-14484	results	_	
80-5	14485-14490	could	_	
80-6	14491-14496	guide	_	
80-7	14497-14504	further	_	
80-8	14505-14516	development	_	
80-9	14517-14519	of	_	
80-10	14520-14523	the	_	
80-11	14524-14531	current	_	
80-12	14532-14535	VFT	_	
80-13	14536-14538	to	_	
80-14	14539-14544	focus	_	
80-15	14545-14549	more	_	
80-16	14550-14552	on	_	
80-17	14553-14557	left	_	
80-18	14558-14561	PFC	_	
80-19	14562-14573	dysfunction	_	
80-20	14573-14574	.	_	

#Text=Namely, repetition of the m-VFT could provide a more sensitive examination of left PFC function in terms of the efficiency of neural processing, in addition to observations from the single m-VFT that is currently used in clinical psychiatry settings in Japan.
81-1	14575-14581	Namely	_	
81-2	14581-14582	,	_	
81-3	14583-14593	repetition	_	
81-4	14594-14596	of	_	
81-5	14597-14600	the	_	
81-6	14601-14606	m-VFT	_	
81-7	14607-14612	could	_	
81-8	14613-14620	provide	_	
81-9	14621-14622	a	_	
81-10	14623-14627	more	_	
81-11	14628-14637	sensitive	_	
81-12	14638-14649	examination	_	
81-13	14650-14652	of	_	
81-14	14653-14657	left	_	
81-15	14658-14661	PFC	_	
81-16	14662-14670	function	_	
81-17	14671-14673	in	_	
81-18	14674-14679	terms	_	
81-19	14680-14682	of	_	
81-20	14683-14686	the	_	
81-21	14687-14697	efficiency	_	
81-22	14698-14700	of	_	
81-23	14701-14707	neural	_	
81-24	14708-14718	processing	_	
81-25	14718-14719	,	_	
81-26	14720-14722	in	_	
81-27	14723-14731	addition	_	
81-28	14732-14734	to	_	
81-29	14735-14747	observations	_	
81-30	14748-14752	from	_	
81-31	14753-14756	the	_	
81-32	14757-14763	single	_	
81-33	14764-14769	m-VFT	_	
81-34	14770-14774	that	_	
81-35	14775-14777	is	_	
81-36	14778-14787	currently	_	
81-37	14788-14792	used	_	
81-38	14793-14795	in	_	
81-39	14796-14804	clinical	_	
81-40	14805-14815	psychiatry	_	
81-41	14816-14824	settings	_	
81-42	14825-14827	in	_	
81-43	14828-14833	Japan	_	
81-44	14833-14834	.	_	

#Text=This enriched information from repeating m-VFT may be useful even for classifying a disease into subtypes that could be associated with some specific aspects of the disease, such as a symptom or treatment response.
82-1	14835-14839	This	_	
82-2	14840-14848	enriched	_	
82-3	14849-14860	information	_	
82-4	14861-14865	from	_	
82-5	14866-14875	repeating	_	
82-6	14876-14881	m-VFT	_	
82-7	14882-14885	may	_	
82-8	14886-14888	be	_	
82-9	14889-14895	useful	_	
82-10	14896-14900	even	_	
82-11	14901-14904	for	_	
82-12	14905-14916	classifying	_	
82-13	14917-14918	a	_	
82-14	14919-14926	disease	_	
82-15	14927-14931	into	_	
82-16	14932-14940	subtypes	_	
82-17	14941-14945	that	_	
82-18	14946-14951	could	_	
82-19	14952-14954	be	_	
82-20	14955-14965	associated	_	
82-21	14966-14970	with	_	
82-22	14971-14975	some	_	
82-23	14976-14984	specific	_	
82-24	14985-14992	aspects	_	
82-25	14993-14995	of	_	
82-26	14996-14999	the	_	
82-27	15000-15007	disease	_	
82-28	15007-15008	,	_	
82-29	15009-15013	such	_	
82-30	15014-15016	as	_	
82-31	15017-15018	a	_	
82-32	15019-15026	symptom	_	
82-33	15027-15029	or	_	
82-34	15030-15039	treatment	_	
82-35	15040-15048	response	_	
82-36	15048-15049	.	_	

#Text=This study had a few methodological limitations.
83-1	15050-15054	This	_	
83-2	15055-15060	study	_	
83-3	15061-15064	had	_	
83-4	15065-15066	a	_	
83-5	15067-15070	few	_	
83-6	15071-15085	methodological	_	
83-7	15086-15097	limitations	_	
83-8	15097-15098	.	_	

#Text=First, the spatial resolution of NIRS was insufficient to precisely annotate the channel locations on the segmentalized cortical surface area.
84-1	15099-15104	First	_	
84-2	15104-15105	,	_	
84-3	15106-15109	the	_	
84-4	15110-15117	spatial	_	
84-5	15118-15128	resolution	_	
84-6	15129-15131	of	_	
84-7	15132-15136	NIRS	_	
84-8	15137-15140	was	_	
84-9	15141-15153	insufficient	_	
84-10	15154-15156	to	_	
84-11	15157-15166	precisely	_	
84-12	15167-15175	annotate	_	
84-13	15176-15179	the	_	
84-14	15180-15187	channel	_	
84-15	15188-15197	locations	_	
84-16	15198-15200	on	_	
84-17	15201-15204	the	_	
84-18	15205-15218	segmentalized	_	
84-19	15219-15227	cortical	_	
84-20	15228-15235	surface	_	
84-21	15236-15240	area	_	
84-22	15240-15241	.	_	

#Text=A study using fMRI in conjunction with NIRS would be valuable in future analysis to validate the exact brain areas where the NIRS channels detected altered activation in this study.
85-1	15242-15243	A	_	
85-2	15244-15249	study	_	
85-3	15250-15255	using	_	
85-4	15256-15260	fMRI	_	
85-5	15261-15263	in	_	
85-6	15264-15275	conjunction	_	
85-7	15276-15280	with	_	
85-8	15281-15285	NIRS	_	
85-9	15286-15291	would	_	
85-10	15292-15294	be	_	
85-11	15295-15303	valuable	_	
85-12	15304-15306	in	_	
85-13	15307-15313	future	_	
85-14	15314-15322	analysis	_	
85-15	15323-15325	to	_	
85-16	15326-15334	validate	_	
85-17	15335-15338	the	_	
85-18	15339-15344	exact	_	
85-19	15345-15350	brain	_	
85-20	15351-15356	areas	_	
85-21	15357-15362	where	_	
85-22	15363-15366	the	_	
85-23	15367-15371	NIRS	_	
85-24	15372-15380	channels	_	
85-25	15381-15389	detected	_	
85-26	15390-15397	altered	_	
85-27	15398-15408	activation	_	
85-28	15409-15411	in	_	
85-29	15412-15416	this	_	
85-30	15417-15422	study	_	
85-31	15422-15423	.	_	

#Text=Second, a certain portion of oxy-Hb signals acquired by the NIRS device contains some local skin blood flow; therefore, we cannot exclude the possibility that the attenuation of m-VFT-induced hemodynamic activation was not fully derived from the brain reaction.
86-1	15424-15430	Second	_	
86-2	15430-15431	,	_	
86-3	15432-15433	a	_	
86-4	15434-15441	certain	_	
86-5	15442-15449	portion	_	
86-6	15450-15452	of	_	
86-7	15453-15459	oxy-Hb	_	
86-8	15460-15467	signals	_	
86-9	15468-15476	acquired	_	
86-10	15477-15479	by	_	
86-11	15480-15483	the	_	
86-12	15484-15488	NIRS	_	
86-13	15489-15495	device	_	
86-14	15496-15504	contains	_	
86-15	15505-15509	some	_	
86-16	15510-15515	local	_	
86-17	15516-15520	skin	_	
86-18	15521-15526	blood	_	
86-19	15527-15531	flow	_	
86-20	15531-15532	;	_	
86-21	15533-15542	therefore	_	
86-22	15542-15543	,	_	
86-23	15544-15546	we	_	
86-24	15547-15553	cannot	_	
86-25	15554-15561	exclude	_	
86-26	15562-15565	the	_	
86-27	15566-15577	possibility	_	
86-28	15578-15582	that	_	
86-29	15583-15586	the	_	
86-30	15587-15598	attenuation	_	
86-31	15599-15601	of	_	
86-32	15602-15615	m-VFT-induced	_	
86-33	15616-15627	hemodynamic	_	
86-34	15628-15638	activation	_	
86-35	15639-15642	was	_	
86-36	15643-15646	not	_	
86-37	15647-15652	fully	_	
86-38	15653-15660	derived	_	
86-39	15661-15665	from	_	
86-40	15666-15669	the	_	
86-41	15670-15675	brain	_	
86-42	15676-15684	reaction	_	
86-43	15684-15685	.	_	

#Text=Nevertheless, based on our results, we must remember that when the VFT is applied in clinical assessments, repeating the VFT (even when switching the designated syllables) attenuates the task-induced hemodynamic activation on some of the frontal channels in NIRS measurements.
87-1	15686-15698	Nevertheless	_	
87-2	15698-15699	,	_	
87-3	15700-15705	based	_	
87-4	15706-15708	on	_	
87-5	15709-15712	our	_	
87-6	15713-15720	results	_	
87-7	15720-15721	,	_	
87-8	15722-15724	we	_	
87-9	15725-15729	must	_	
87-10	15730-15738	remember	_	
87-11	15739-15743	that	_	
87-12	15744-15748	when	_	
87-13	15749-15752	the	_	
87-14	15753-15756	VFT	_	
87-15	15757-15759	is	_	
87-16	15760-15767	applied	_	
87-17	15768-15770	in	_	
87-18	15771-15779	clinical	_	
87-19	15780-15791	assessments	_	
87-20	15791-15792	,	_	
87-21	15793-15802	repeating	_	
87-22	15803-15806	the	_	
87-23	15807-15810	VFT	_	
87-24	15811-15812	(	_	
87-25	15812-15816	even	_	
87-26	15817-15821	when	_	
87-27	15822-15831	switching	_	
87-28	15832-15835	the	_	
87-29	15836-15846	designated	_	
87-30	15847-15856	syllables	_	
87-31	15856-15857	)	_	
87-32	15858-15868	attenuates	_	
87-33	15869-15872	the	_	
87-34	15873-15885	task-induced	_	
87-35	15886-15897	hemodynamic	_	
87-36	15898-15908	activation	_	
87-37	15909-15911	on	_	
87-38	15912-15916	some	_	
87-39	15917-15919	of	_	
87-40	15920-15923	the	_	
87-41	15924-15931	frontal	_	
87-42	15932-15940	channels	_	
87-43	15941-15943	in	_	
87-44	15944-15948	NIRS	_	
87-45	15949-15961	measurements	_	
87-46	15961-15962	.	_	

#Text=In this study, we found that repetition of the m-VFT attenuated left PFC activation in NIRS measurements.
88-1	15963-15965	In	_	
88-2	15966-15970	this	_	
88-3	15971-15976	study	_	
88-4	15976-15977	,	_	
88-5	15978-15980	we	_	
88-6	15981-15986	found	_	
88-7	15987-15991	that	_	
88-8	15992-16002	repetition	_	
88-9	16003-16005	of	_	
88-10	16006-16009	the	_	
88-11	16010-16015	m-VFT	_	
88-12	16016-16026	attenuated	_	
88-13	16027-16031	left	_	
88-14	16032-16035	PFC	_	
88-15	16036-16046	activation	_	
88-16	16047-16049	in	_	
88-17	16050-16054	NIRS	_	
88-18	16055-16067	measurements	_	
88-19	16067-16068	.	_	

#Text=This finding suggests that left PFC is a sensitive region for processing the m-VFT.
89-1	16069-16073	This	_	
89-2	16074-16081	finding	_	
89-3	16082-16090	suggests	_	
89-4	16091-16095	that	_	
89-5	16096-16100	left	_	
89-6	16101-16104	PFC	_	
89-7	16105-16107	is	_	
89-8	16108-16109	a	_	
89-9	16110-16119	sensitive	_	
89-10	16120-16126	region	_	
89-11	16127-16130	for	_	
89-12	16131-16141	processing	_	
89-13	16142-16145	the	_	
89-14	16146-16151	m-VFT	_	
89-15	16151-16152	.	_	

#Text=This would support Klumpp’s hypothesis, which points out a possible association between the switching in VFT and sensitivity of the left frontal dysfunction.
90-1	16153-16157	This	_	
90-2	16158-16163	would	_	
90-3	16164-16171	support	_	
90-4	16172-16178	Klumpp	_	
90-5	16178-16179	’	_	
90-6	16179-16180	s	_	
90-7	16181-16191	hypothesis	_	
90-8	16191-16192	,	_	
90-9	16193-16198	which	_	
90-10	16199-16205	points	_	
90-11	16206-16209	out	_	
90-12	16210-16211	a	_	
90-13	16212-16220	possible	_	
90-14	16221-16232	association	_	
90-15	16233-16240	between	_	
90-16	16241-16244	the	_	
90-17	16245-16254	switching	_	
90-18	16255-16257	in	_	
90-19	16258-16261	VFT	_	
90-20	16262-16265	and	_	
90-21	16266-16277	sensitivity	_	
90-22	16278-16280	of	_	
90-23	16281-16284	the	_	
90-24	16285-16289	left	_	
90-25	16290-16297	frontal	_	
90-26	16298-16309	dysfunction	_	
90-27	16309-16310	.	_	

#Text=Taken together, these results indicate that repetition of the m-VFT may enhance the current, single-use m-VFT by focusing more on the left PFC, whose dysfunction has been reported in several psychiatric diseases such as major depressive disorder, bipolar disorder, and schizophrenia.
91-1	16311-16316	Taken	_	
91-2	16317-16325	together	_	
91-3	16325-16326	,	_	
91-4	16327-16332	these	_	
91-5	16333-16340	results	_	
91-6	16341-16349	indicate	_	
91-7	16350-16354	that	_	
91-8	16355-16365	repetition	_	
91-9	16366-16368	of	_	
91-10	16369-16372	the	_	
91-11	16373-16378	m-VFT	_	
91-12	16379-16382	may	_	
91-13	16383-16390	enhance	_	
91-14	16391-16394	the	_	
91-15	16395-16402	current	_	
91-16	16402-16403	,	_	
91-17	16404-16414	single-use	_	
91-18	16415-16420	m-VFT	_	
91-19	16421-16423	by	_	
91-20	16424-16432	focusing	_	
91-21	16433-16437	more	_	
91-22	16438-16440	on	_	
91-23	16441-16444	the	_	
91-24	16445-16449	left	_	
91-25	16450-16453	PFC	_	
91-26	16453-16454	,	_	
91-27	16455-16460	whose	_	
91-28	16461-16472	dysfunction	_	
91-29	16473-16476	has	_	
91-30	16477-16481	been	_	
91-31	16482-16490	reported	_	
91-32	16491-16493	in	_	
91-33	16494-16501	several	_	
91-34	16502-16513	psychiatric	_	
91-35	16514-16522	diseases	_	
91-36	16523-16527	such	_	
91-37	16528-16530	as	_	
91-38	16531-16536	major	_	
91-39	16537-16547	depressive	_	
91-40	16548-16556	disorder	_	
91-41	16556-16557	,	_	
91-42	16558-16565	bipolar	_	
91-43	16566-16574	disorder	_	
91-44	16574-16575	,	_	
91-45	16576-16579	and	_	
91-46	16580-16593	schizophrenia	_	
91-47	16593-16594	.	_	

#Text=Further studies should examine the task-induced hemodynamic changes in psychiatric diseases, from the viewpoint of their particular pathophysiologies.
92-1	16595-16602	Further	_	
92-2	16603-16610	studies	_	
92-3	16611-16617	should	_	
92-4	16618-16625	examine	_	
92-5	16626-16629	the	_	
92-6	16630-16642	task-induced	_	
92-7	16643-16654	hemodynamic	_	
92-8	16655-16662	changes	_	
92-9	16663-16665	in	_	
92-10	16666-16677	psychiatric	_	
92-11	16678-16686	diseases	_	
92-12	16686-16687	,	_	
92-13	16688-16692	from	_	
92-14	16693-16696	the	_	
92-15	16697-16706	viewpoint	_	
92-16	16707-16709	of	_	
92-17	16710-16715	their	_	
92-18	16716-16726	particular	_	
92-19	16727-16744	pathophysiologies	_	
92-20	16744-16745	.	_	

#Text=Supporting information
#Text=References
#Text=Application of functional near-infrared spectroscopy in psychiatry
#Text=Neuroscience: Thought experiment
#Text=Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive activation study
#Text=Reduced frontopolar activation during verbal fluency task in schizo-phrenia: amulti-channelnear-infraredspectroscopystudy
#Text=Frontal and right temporal activations correlate negatively with depressionse verity during verbal fluency task: a multi channel near-infrared spectroscopy study
#Text=Neuroimaging-aided differential diagnosis of the depressive state
#Text=A discriminant model of mental disorders based on wave form patterns obtained by multi-channel near-infrared spectroscopy
#Text=Clustering and switching as two components of verbal fluency: evidence from younger and older healthy adults
#Text=Qualitative analysis of verbal fluency output: review and comparison of several scoring methods
#Text=Generating 'tiger' as an animal name or a word beginning with T: differences in brain activation
#Text=A comparison of rCBF patterns during letter and semantic fluency
#Text=Specialisation in Broca‘s region for semantic, phonological, and syntactic fluency?
93-1	16746-16756	Supporting	_	
93-2	16757-16768	information	_	
93-3	16769-16779	References	_	
93-4	16780-16791	Application	_	
93-5	16792-16794	of	_	
93-6	16795-16805	functional	_	
93-7	16806-16819	near-infrared	_	
93-8	16820-16832	spectroscopy	_	
93-9	16833-16835	in	_	
93-10	16836-16846	psychiatry	_	
93-11	16847-16859	Neuroscience	_	
93-12	16859-16860	:	_	
93-13	16861-16868	Thought	_	
93-14	16869-16879	experiment	_	
93-15	16880-16892	Multichannel	_	
93-16	16893-16906	near-infrared	_	
93-17	16907-16919	spectroscopy	_	
93-18	16920-16922	in	_	
93-19	16923-16933	depression	_	
93-20	16934-16937	and	_	
93-21	16938-16951	schizophrenia	_	
93-22	16951-16952	:	_	
93-23	16953-16962	cognitive	_	
93-24	16963-16973	activation	_	
93-25	16974-16979	study	_	
93-26	16980-16987	Reduced	_	
93-27	16988-16999	frontopolar	_	
93-28	17000-17010	activation	_	
93-29	17011-17017	during	_	
93-30	17018-17024	verbal	_	
93-31	17025-17032	fluency	_	
93-32	17033-17037	task	_	
93-33	17038-17040	in	_	
93-34	17041-17055	schizo-phrenia	_	
93-35	17055-17056	:	_	
93-36	17057-17101	amulti-channelnear-infraredspectroscopystudy	_	
93-37	17102-17109	Frontal	_	
93-38	17110-17113	and	_	
93-39	17114-17119	right	_	
93-40	17120-17128	temporal	_	
93-41	17129-17140	activations	_	
93-42	17141-17150	correlate	_	
93-43	17151-17161	negatively	_	
93-44	17162-17166	with	_	
93-45	17167-17179	depressionse	_	
93-46	17180-17186	verity	_	
93-47	17187-17193	during	_	
93-48	17194-17200	verbal	_	
93-49	17201-17208	fluency	_	
93-50	17209-17213	task	_	
93-51	17213-17214	:	_	
93-52	17215-17216	a	_	
93-53	17217-17222	multi	_	
93-54	17223-17230	channel	_	
93-55	17231-17244	near-infrared	_	
93-56	17245-17257	spectroscopy	_	
93-57	17258-17263	study	_	
93-58	17264-17282	Neuroimaging-aided	_	
93-59	17283-17295	differential	_	
93-60	17296-17305	diagnosis	_	
93-61	17306-17308	of	_	
93-62	17309-17312	the	_	
93-63	17313-17323	depressive	_	
93-64	17324-17329	state	_	
93-65	17330-17331	A	_	
93-66	17332-17344	discriminant	_	
93-67	17345-17350	model	_	
93-68	17351-17353	of	_	
93-69	17354-17360	mental	_	
93-70	17361-17370	disorders	_	
93-71	17371-17376	based	_	
93-72	17377-17379	on	_	
93-73	17380-17384	wave	_	
93-74	17385-17389	form	_	
93-75	17390-17398	patterns	_	
93-76	17399-17407	obtained	_	
93-77	17408-17410	by	_	
93-78	17411-17424	multi-channel	_	
93-79	17425-17438	near-infrared	_	
93-80	17439-17451	spectroscopy	_	
93-81	17452-17462	Clustering	_	
93-82	17463-17466	and	_	
93-83	17467-17476	switching	_	
93-84	17477-17479	as	_	
93-85	17480-17483	two	_	
93-86	17484-17494	components	_	
93-87	17495-17497	of	_	
93-88	17498-17504	verbal	_	
93-89	17505-17512	fluency	_	
93-90	17512-17513	:	_	
93-91	17514-17522	evidence	_	
93-92	17523-17527	from	_	
93-93	17528-17535	younger	_	
93-94	17536-17539	and	_	
93-95	17540-17545	older	_	
93-96	17546-17553	healthy	_	
93-97	17554-17560	adults	_	
93-98	17561-17572	Qualitative	_	
93-99	17573-17581	analysis	_	
93-100	17582-17584	of	_	
93-101	17585-17591	verbal	_	
93-102	17592-17599	fluency	_	
93-103	17600-17606	output	_	
93-104	17606-17607	:	_	
93-105	17608-17614	review	_	
93-106	17615-17618	and	_	
93-107	17619-17629	comparison	_	
93-108	17630-17632	of	_	
93-109	17633-17640	several	_	
93-110	17641-17648	scoring	_	
93-111	17649-17656	methods	_	
93-112	17657-17667	Generating	_	
93-113	17668-17669	'	_	
93-114	17669-17674	tiger	_	
93-115	17674-17675	'	_	
93-116	17676-17678	as	_	
93-117	17679-17681	an	_	
93-118	17682-17688	animal	_	
93-119	17689-17693	name	_	
93-120	17694-17696	or	_	
93-121	17697-17698	a	_	
93-122	17699-17703	word	_	
93-123	17704-17713	beginning	_	
93-124	17714-17718	with	_	
93-125	17719-17720	T	_	
93-126	17720-17721	:	_	
93-127	17722-17733	differences	_	
93-128	17734-17736	in	_	
93-129	17737-17742	brain	_	
93-130	17743-17753	activation	_	
93-131	17754-17755	A	_	
93-132	17756-17766	comparison	_	
93-133	17767-17769	of	_	
93-134	17770-17774	rCBF	_	
93-135	17775-17783	patterns	_	
93-136	17784-17790	during	_	
93-137	17791-17797	letter	_	
93-138	17798-17801	and	_	
93-139	17802-17810	semantic	_	
93-140	17811-17818	fluency	_	
93-141	17819-17833	Specialisation	_	
93-142	17834-17836	in	_	
93-143	17837-17842	Broca	_	
93-144	17842-17843	‘	_	
93-145	17843-17844	s	_	
93-146	17845-17851	region	_	
93-147	17852-17855	for	_	
93-148	17856-17864	semantic	_	
93-149	17864-17865	,	_	
93-150	17866-17878	phonological	_	
93-151	17878-17879	,	_	
93-152	17880-17883	and	_	
93-153	17884-17893	syntactic	_	
93-154	17894-17901	fluency	_	
93-155	17901-17902	?	_	

#Text=Clustering and switching on verbal fluency: the effects of focal frontal- and temporal-lobe lesions
#Text=Role of the left inferior frontal gyrus in covert word retrieval: neural correlates of switching during verbal fluency
#Text=Theassessmentandanalysisofhandedness: the Edinburgh inventory
#Text=Methods of quantitating cerebral near infrared spectroscopy data
#Text=Decrease in parietal cerebral hemoglobin oxygenation during performance of a verbal fluency task in patients with Alzheimer's disease monitored by means of near-infrared spectroscopy (NIRS)—correlation with simultaneous rCBF-PET measurements
#Text=Near-infrared light propagation in an adult head model.
94-1	17903-17913	Clustering	_	
94-2	17914-17917	and	_	
94-3	17918-17927	switching	_	
94-4	17928-17930	on	_	
94-5	17931-17937	verbal	_	
94-6	17938-17945	fluency	_	
94-7	17945-17946	:	_	
94-8	17947-17950	the	_	
94-9	17951-17958	effects	_	
94-10	17959-17961	of	_	
94-11	17962-17967	focal	_	
94-12	17968-17975	frontal	_	
94-13	17975-17976	-	_	
94-14	17977-17980	and	_	
94-15	17981-17994	temporal-lobe	_	
94-16	17995-18002	lesions	_	
94-17	18003-18007	Role	_	
94-18	18008-18010	of	_	
94-19	18011-18014	the	_	
94-20	18015-18019	left	_	
94-21	18020-18028	inferior	_	
94-22	18029-18036	frontal	_	
94-23	18037-18042	gyrus	_	
94-24	18043-18045	in	_	
94-25	18046-18052	covert	_	
94-26	18053-18057	word	_	
94-27	18058-18067	retrieval	_	
94-28	18067-18068	:	_	
94-29	18069-18075	neural	_	
94-30	18076-18086	correlates	_	
94-31	18087-18089	of	_	
94-32	18090-18099	switching	_	
94-33	18100-18106	during	_	
94-34	18107-18113	verbal	_	
94-35	18114-18121	fluency	_	
94-36	18122-18158	Theassessmentandanalysisofhandedness	_	
94-37	18158-18159	:	_	
94-38	18160-18163	the	_	
94-39	18164-18173	Edinburgh	_	
94-40	18174-18183	inventory	_	
94-41	18184-18191	Methods	_	
94-42	18192-18194	of	_	
94-43	18195-18207	quantitating	_	
94-44	18208-18216	cerebral	_	
94-45	18217-18221	near	_	
94-46	18222-18230	infrared	_	
94-47	18231-18243	spectroscopy	_	
94-48	18244-18248	data	_	
94-49	18249-18257	Decrease	_	
94-50	18258-18260	in	_	
94-51	18261-18269	parietal	_	
94-52	18270-18278	cerebral	_	
94-53	18279-18289	hemoglobin	_	
94-54	18290-18301	oxygenation	_	
94-55	18302-18308	during	_	
94-56	18309-18320	performance	_	
94-57	18321-18323	of	_	
94-58	18324-18325	a	_	
94-59	18326-18332	verbal	_	
94-60	18333-18340	fluency	_	
94-61	18341-18345	task	_	
94-62	18346-18348	in	_	
94-63	18349-18357	patients	_	
94-64	18358-18362	with	_	
94-65	18363-18374	Alzheimer's	_	
94-66	18375-18382	disease	_	
94-67	18383-18392	monitored	_	
94-68	18393-18395	by	_	
94-69	18396-18401	means	_	
94-70	18402-18404	of	_	
94-71	18405-18418	near-infrared	_	
94-72	18419-18431	spectroscopy	_	
94-73	18432-18433	(	_	
94-74	18433-18437	NIRS	_	
94-75	18437-18438	)	_	
94-76	18438-18439	—	_	
94-77	18439-18450	correlation	_	
94-78	18451-18455	with	_	
94-79	18456-18468	simultaneous	_	
94-80	18469-18477	rCBF-PET	_	
94-81	18478-18490	measurements	_	
94-82	18491-18504	Near-infrared	_	
94-83	18505-18510	light	_	
94-84	18511-18522	propagation	_	
94-85	18523-18525	in	_	
94-86	18526-18528	an	_	
94-87	18529-18534	adult	_	
94-88	18535-18539	head	_	
94-89	18540-18545	model	_	
94-90	18545-18546	.	_	

#Text=II.
95-1	18547-18549	II	_	
95-2	18549-18550	.	_	

#Text=Effect of superficial tissue thickness on the sensitivity of the near-infrared spectroscopy signal
#Text=Investigation of human brain hemodynamics by simultaneous near-infrared spectroscopy and functional magnetic resonance imaging
#Text=Automated Talairach atlas labels for functional brain mapping
#Text=Spatial registration of multi-channel multi-subject fNIRS data to MNI space without MRI
#Text=Virtual spatial registration of stand-alone fNIRS data to MNI space
#Text=Right temporal activation differs between melancholia and nonmelancholic depression: a multichannel near-infrared spectroscopy study
#Text=brain-lab.jp [Internet].
96-1	18551-18557	Effect	_	
96-2	18558-18560	of	_	
96-3	18561-18572	superficial	_	
96-4	18573-18579	tissue	_	
96-5	18580-18589	thickness	_	
96-6	18590-18592	on	_	
96-7	18593-18596	the	_	
96-8	18597-18608	sensitivity	_	
96-9	18609-18611	of	_	
96-10	18612-18615	the	_	
96-11	18616-18629	near-infrared	_	
96-12	18630-18642	spectroscopy	_	
96-13	18643-18649	signal	_	
96-14	18650-18663	Investigation	_	
96-15	18664-18666	of	_	
96-16	18667-18672	human	_	
96-17	18673-18678	brain	_	
96-18	18679-18691	hemodynamics	_	
96-19	18692-18694	by	_	
96-20	18695-18707	simultaneous	_	
96-21	18708-18721	near-infrared	_	
96-22	18722-18734	spectroscopy	_	
96-23	18735-18738	and	_	
96-24	18739-18749	functional	_	
96-25	18750-18758	magnetic	_	
96-26	18759-18768	resonance	_	
96-27	18769-18776	imaging	_	
96-28	18777-18786	Automated	_	
96-29	18787-18796	Talairach	_	
96-30	18797-18802	atlas	_	
96-31	18803-18809	labels	_	
96-32	18810-18813	for	_	
96-33	18814-18824	functional	_	
96-34	18825-18830	brain	_	
96-35	18831-18838	mapping	_	
96-36	18839-18846	Spatial	_	
96-37	18847-18859	registration	_	
96-38	18860-18862	of	_	
96-39	18863-18876	multi-channel	_	
96-40	18877-18890	multi-subject	_	
96-41	18891-18896	fNIRS	_	
96-42	18897-18901	data	_	
96-43	18902-18904	to	_	
96-44	18905-18908	MNI	_	
96-45	18909-18914	space	_	
96-46	18915-18922	without	_	
96-47	18923-18926	MRI	_	
96-48	18927-18934	Virtual	_	
96-49	18935-18942	spatial	_	
96-50	18943-18955	registration	_	
96-51	18956-18958	of	_	
96-52	18959-18970	stand-alone	_	
96-53	18971-18976	fNIRS	_	
96-54	18977-18981	data	_	
96-55	18982-18984	to	_	
96-56	18985-18988	MNI	_	
96-57	18989-18994	space	_	
96-58	18995-19000	Right	_	
96-59	19001-19009	temporal	_	
96-60	19010-19020	activation	_	
96-61	19021-19028	differs	_	
96-62	19029-19036	between	_	
96-63	19037-19048	melancholia	_	
96-64	19049-19052	and	_	
96-65	19053-19067	nonmelancholic	_	
96-66	19068-19078	depression	_	
96-67	19078-19079	:	_	
96-68	19080-19081	a	_	
96-69	19082-19094	multichannel	_	
96-70	19095-19108	near-infrared	_	
96-71	19109-19121	spectroscopy	_	
96-72	19122-19127	study	_	
96-73	19128-19140	brain-lab.jp	_	
96-74	19141-19142	[	_	
96-75	19142-19150	Internet	_	
96-76	19150-19151	]	_	
96-77	19151-19152	.	_	

#Text=Tokyo: Dan's Lab at Chuo University; c2010 [cited 2017 July 11].
97-1	19153-19158	Tokyo	_	
97-2	19158-19159	:	_	
97-3	19160-19165	Dan's	_	
97-4	19166-19169	Lab	_	
97-5	19170-19172	at	_	
97-6	19173-19177	Chuo	_	
97-7	19178-19188	University	_	
97-8	19188-19189	;	_	
97-9	19190-19195	c2010	_	
97-10	19196-19197	[	_	
97-11	19197-19202	cited	_	
97-12	19203-19207	2017	_	
97-13	19208-19212	July	_	
97-14	19213-19215	11	_	
97-15	19215-19216	]	_	
97-16	19216-19217	.	_	

#Text=Available from: http://www.jichi.ac.jp/brainlab/virtual_registration/Result3x11.html.
98-1	19218-19227	Available	_	
98-2	19228-19232	from	_	
98-3	19232-19233	:	_	
98-4	19234-19238	http	_	
98-5	19238-19239	:	_	
98-6	19239-19240	/	_	
98-7	19240-19241	/	_	
98-8	19241-19256	www.jichi.ac.jp	_	
98-9	19256-19257	/	_	
98-10	19257-19265	brainlab	_	
98-11	19265-19266	/	_	
98-12	19266-19286	virtual_registration	_	
98-13	19286-19287	/	_	
98-14	19287-19297	Result3x11	_	
98-15	19297-19298	.	_	
98-16	19298-19302	html	_	
98-17	19302-19303	.	_	

#Text=Phonology, semantics, and the role of the left inferior prefrontal cortex
#Text=The role of left prefrontal cortex in language and memory
#Text=Cellular basis of working memory
#Text=Dorsolateral prefrontal contributions to human working memory
#Text=Dissociating verbal and spatial working memory using PET
#Text=Practice-related functional activation changes in a working memory task
#Text=Functional anatomical correlates of controlled and automatic processing
#Text=A functional MRI study of the influence of practice on component processes of working memory
#Text=Increased neural efficiency with repeated performance of a working memory task is information-type dependent
#Text=Increased neural efficiency in the temporal association cortex as the result of semantic task repetition
#Text=I.
99-1	19304-19313	Phonology	_	
99-2	19313-19314	,	_	
99-3	19315-19324	semantics	_	
99-4	19324-19325	,	_	
99-5	19326-19329	and	_	
99-6	19330-19333	the	_	
99-7	19334-19338	role	_	
99-8	19339-19341	of	_	
99-9	19342-19345	the	_	
99-10	19346-19350	left	_	
99-11	19351-19359	inferior	_	
99-12	19360-19370	prefrontal	_	
99-13	19371-19377	cortex	_	
99-14	19378-19381	The	_	
99-15	19382-19386	role	_	
99-16	19387-19389	of	_	
99-17	19390-19394	left	_	
99-18	19395-19405	prefrontal	_	
99-19	19406-19412	cortex	_	
99-20	19413-19415	in	_	
99-21	19416-19424	language	_	
99-22	19425-19428	and	_	
99-23	19429-19435	memory	_	
99-24	19436-19444	Cellular	_	
99-25	19445-19450	basis	_	
99-26	19451-19453	of	_	
99-27	19454-19461	working	_	
99-28	19462-19468	memory	_	
99-29	19469-19481	Dorsolateral	_	
99-30	19482-19492	prefrontal	_	
99-31	19493-19506	contributions	_	
99-32	19507-19509	to	_	
99-33	19510-19515	human	_	
99-34	19516-19523	working	_	
99-35	19524-19530	memory	_	
99-36	19531-19543	Dissociating	_	
99-37	19544-19550	verbal	_	
99-38	19551-19554	and	_	
99-39	19555-19562	spatial	_	
99-40	19563-19570	working	_	
99-41	19571-19577	memory	_	
99-42	19578-19583	using	_	
99-43	19584-19587	PET	_	
99-44	19588-19604	Practice-related	_	
99-45	19605-19615	functional	_	
99-46	19616-19626	activation	_	
99-47	19627-19634	changes	_	
99-48	19635-19637	in	_	
99-49	19638-19639	a	_	
99-50	19640-19647	working	_	
99-51	19648-19654	memory	_	
99-52	19655-19659	task	_	
99-53	19660-19670	Functional	_	
99-54	19671-19681	anatomical	_	
99-55	19682-19692	correlates	_	
99-56	19693-19695	of	_	
99-57	19696-19706	controlled	_	
99-58	19707-19710	and	_	
99-59	19711-19720	automatic	_	
99-60	19721-19731	processing	_	
99-61	19732-19733	A	_	
99-62	19734-19744	functional	_	
99-63	19745-19748	MRI	_	
99-64	19749-19754	study	_	
99-65	19755-19757	of	_	
99-66	19758-19761	the	_	
99-67	19762-19771	influence	_	
99-68	19772-19774	of	_	
99-69	19775-19783	practice	_	
99-70	19784-19786	on	_	
99-71	19787-19796	component	_	
99-72	19797-19806	processes	_	
99-73	19807-19809	of	_	
99-74	19810-19817	working	_	
99-75	19818-19824	memory	_	
99-76	19825-19834	Increased	_	
99-77	19835-19841	neural	_	
99-78	19842-19852	efficiency	_	
99-79	19853-19857	with	_	
99-80	19858-19866	repeated	_	
99-81	19867-19878	performance	_	
99-82	19879-19881	of	_	
99-83	19882-19883	a	_	
99-84	19884-19891	working	_	
99-85	19892-19898	memory	_	
99-86	19899-19903	task	_	
99-87	19904-19906	is	_	
99-88	19907-19923	information-type	_	
99-89	19924-19933	dependent	_	
99-90	19934-19943	Increased	_	
99-91	19944-19950	neural	_	
99-92	19951-19961	efficiency	_	
99-93	19962-19964	in	_	
99-94	19965-19968	the	_	
99-95	19969-19977	temporal	_	
99-96	19978-19989	association	_	
99-97	19990-19996	cortex	_	
99-98	19997-19999	as	_	
99-99	20000-20003	the	_	
99-100	20004-20010	result	_	
99-101	20011-20013	of	_	
99-102	20014-20022	semantic	_	
99-103	20023-20027	task	_	
99-104	20028-20038	repetition	_	
99-105	20039-20040	I	_	
99-106	20040-20041	.	_	

#Text=PET studies of memory: novel and practiced free recall of complex narratives
#Text=Commonalities and differences in the working memory components underlying letter and category fluency tasks: a dual-task investigation
#Text=What do verbal fluency tasks measure?
100-1	20042-20045	PET	_	
100-2	20046-20053	studies	_	
100-3	20054-20056	of	_	
100-4	20057-20063	memory	_	
100-5	20063-20064	:	_	
100-6	20065-20070	novel	_	
100-7	20071-20074	and	_	
100-8	20075-20084	practiced	_	
100-9	20085-20089	free	_	
100-10	20090-20096	recall	_	
100-11	20097-20099	of	_	
100-12	20100-20107	complex	_	
100-13	20108-20118	narratives	_	
100-14	20119-20132	Commonalities	_	
100-15	20133-20136	and	_	
100-16	20137-20148	differences	_	
100-17	20149-20151	in	_	
100-18	20152-20155	the	_	
100-19	20156-20163	working	_	
100-20	20164-20170	memory	_	
100-21	20171-20181	components	_	
100-22	20182-20192	underlying	_	
100-23	20193-20199	letter	_	
100-24	20200-20203	and	_	
100-25	20204-20212	category	_	
100-26	20213-20220	fluency	_	
100-27	20221-20226	tasks	_	
100-28	20226-20227	:	_	
100-29	20228-20229	a	_	
100-30	20230-20239	dual-task	_	
100-31	20240-20253	investigation	_	
100-32	20254-20258	What	_	
100-33	20259-20261	do	_	
100-34	20262-20268	verbal	_	
100-35	20269-20276	fluency	_	
100-36	20277-20282	tasks	_	
100-37	20283-20290	measure	_	
100-38	20290-20291	?	_	

#Text=Predictors of verbal fluency performance in older adults
#Text=Practice-related effects demonstrate complementary roles of anterior cingulate and prefrontal cortices in attentional control
#Text=A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus
#Text=Revisiting the functional specialization of left inferior frontal gyrus in phonological and semantic fluency: the crucial role of task demands and individual ability
#Text=Attenuated left prefrontal activation during a verbal fluency task in patients with depression
#Text=Frontal lobe function in bipolar disorder: a multichannel near-infrared spectroscopy study
#Text=Review of brain functioning in depression for semantic processing and verbal fluency
#Text=Kawagoe R Differences in the pulsatile component of the skin hemodynamic response to verbal fluency tasks in the forehead and the fingertip
#Text=Estimation of skin blood flow artefacts in nirs signals during a verbal fluency task
#Text=The ENIGMA Bipolar Disorder Working Group.
101-1	20292-20302	Predictors	_	
101-2	20303-20305	of	_	
101-3	20306-20312	verbal	_	
101-4	20313-20320	fluency	_	
101-5	20321-20332	performance	_	
101-6	20333-20335	in	_	
101-7	20336-20341	older	_	
101-8	20342-20348	adults	_	
101-9	20349-20365	Practice-related	_	
101-10	20366-20373	effects	_	
101-11	20374-20385	demonstrate	_	
101-12	20386-20399	complementary	_	
101-13	20400-20405	roles	_	
101-14	20406-20408	of	_	
101-15	20409-20417	anterior	_	
101-16	20418-20427	cingulate	_	
101-17	20428-20431	and	_	
101-18	20432-20442	prefrontal	_	
101-19	20443-20451	cortices	_	
101-20	20452-20454	in	_	
101-21	20455-20466	attentional	_	
101-22	20467-20474	control	_	
101-23	20475-20476	A	_	
101-24	20477-20487	systematic	_	
101-25	20488-20494	review	_	
101-26	20495-20498	and	_	
101-27	20499-20511	quantitative	_	
101-28	20512-20521	appraisal	_	
101-29	20522-20524	of	_	
101-30	20525-20529	fMRI	_	
101-31	20530-20537	studies	_	
101-32	20538-20540	of	_	
101-33	20541-20547	verbal	_	
101-34	20548-20555	fluency	_	
101-35	20555-20556	:	_	
101-36	20557-20561	role	_	
101-37	20562-20564	of	_	
101-38	20565-20568	the	_	
101-39	20569-20573	left	_	
101-40	20574-20582	inferior	_	
101-41	20583-20590	frontal	_	
101-42	20591-20596	gyrus	_	
101-43	20597-20607	Revisiting	_	
101-44	20608-20611	the	_	
101-45	20612-20622	functional	_	
101-46	20623-20637	specialization	_	
101-47	20638-20640	of	_	
101-48	20641-20645	left	_	
101-49	20646-20654	inferior	_	
101-50	20655-20662	frontal	_	
101-51	20663-20668	gyrus	_	
101-52	20669-20671	in	_	
101-53	20672-20684	phonological	_	
101-54	20685-20688	and	_	
101-55	20689-20697	semantic	_	
101-56	20698-20705	fluency	_	
101-57	20705-20706	:	_	
101-58	20707-20710	the	_	
101-59	20711-20718	crucial	_	
101-60	20719-20723	role	_	
101-61	20724-20726	of	_	
101-62	20727-20731	task	_	
101-63	20732-20739	demands	_	
101-64	20740-20743	and	_	
101-65	20744-20754	individual	_	
101-66	20755-20762	ability	_	
101-67	20763-20773	Attenuated	_	
101-68	20774-20778	left	_	
101-69	20779-20789	prefrontal	_	
101-70	20790-20800	activation	_	
101-71	20801-20807	during	_	
101-72	20808-20809	a	_	
101-73	20810-20816	verbal	_	
101-74	20817-20824	fluency	_	
101-75	20825-20829	task	_	
101-76	20830-20832	in	_	
101-77	20833-20841	patients	_	
101-78	20842-20846	with	_	
101-79	20847-20857	depression	_	
101-80	20858-20865	Frontal	_	
101-81	20866-20870	lobe	_	
101-82	20871-20879	function	_	
101-83	20880-20882	in	_	
101-84	20883-20890	bipolar	_	
101-85	20891-20899	disorder	_	
101-86	20899-20900	:	_	
101-87	20901-20902	a	_	
101-88	20903-20915	multichannel	_	
101-89	20916-20929	near-infrared	_	
101-90	20930-20942	spectroscopy	_	
101-91	20943-20948	study	_	
101-92	20949-20955	Review	_	
101-93	20956-20958	of	_	
101-94	20959-20964	brain	_	
101-95	20965-20976	functioning	_	
101-96	20977-20979	in	_	
101-97	20980-20990	depression	_	
101-98	20991-20994	for	_	
101-99	20995-21003	semantic	_	
101-100	21004-21014	processing	_	
101-101	21015-21018	and	_	
101-102	21019-21025	verbal	_	
101-103	21026-21033	fluency	_	
101-104	21034-21041	Kawagoe	_	
101-105	21042-21043	R	_	
101-106	21044-21055	Differences	_	
101-107	21056-21058	in	_	
101-108	21059-21062	the	_	
101-109	21063-21072	pulsatile	_	
101-110	21073-21082	component	_	
101-111	21083-21085	of	_	
101-112	21086-21089	the	_	
101-113	21090-21094	skin	_	
101-114	21095-21106	hemodynamic	_	
101-115	21107-21115	response	_	
101-116	21116-21118	to	_	
101-117	21119-21125	verbal	_	
101-118	21126-21133	fluency	_	
101-119	21134-21139	tasks	_	
101-120	21140-21142	in	_	
101-121	21143-21146	the	_	
101-122	21147-21155	forehead	_	
101-123	21156-21159	and	_	
101-124	21160-21163	the	_	
101-125	21164-21173	fingertip	_	
101-126	21174-21184	Estimation	_	
101-127	21185-21187	of	_	
101-128	21188-21192	skin	_	
101-129	21193-21198	blood	_	
101-130	21199-21203	flow	_	
101-131	21204-21213	artefacts	_	
101-132	21214-21216	in	_	
101-133	21217-21221	nirs	_	
101-134	21222-21229	signals	_	
101-135	21230-21236	during	_	
101-136	21237-21238	a	_	
101-137	21239-21245	verbal	_	
101-138	21246-21253	fluency	_	
101-139	21254-21258	task	_	
101-140	21259-21262	The	_	
101-141	21263-21269	ENIGMA	_	
101-142	21270-21277	Bipolar	_	
101-143	21278-21286	Disorder	_	
101-144	21287-21294	Working	_	
101-145	21295-21300	Group	_	
101-146	21300-21301	.	_	

#Text=Cortical abnormalities in bipolar disorder: an MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group.
102-1	21302-21310	Cortical	_	
102-2	21311-21324	abnormalities	_	
102-3	21325-21327	in	_	
102-4	21328-21335	bipolar	_	
102-5	21336-21344	disorder	_	
102-6	21344-21345	:	_	
102-7	21346-21348	an	_	
102-8	21349-21352	MRI	_	
102-9	21353-21361	analysis	_	
102-10	21362-21364	of	_	
102-11	21365-21369	6503	_	
102-12	21370-21381	individuals	_	
102-13	21382-21386	from	_	
102-14	21387-21390	the	_	
102-15	21391-21397	ENIGMA	_	
102-16	21398-21405	Bipolar	_	
102-17	21406-21414	Disorder	_	
102-18	21415-21422	Working	_	
102-19	21423-21428	Group	_	
102-20	21428-21429	.	_	

#Text=Molecular Psychiatry 2017 (in press)
#Text=The functional neuroanatomy of symptom dimensions in schizophrenia: a qualitative and quantitative review of a persistent question
103-1	21430-21439	Molecular	_	
103-2	21440-21450	Psychiatry	_	
103-3	21451-21455	2017	_	
103-4	21456-21457	(	_	
103-5	21457-21459	in	_	
103-6	21460-21465	press	_	
103-7	21465-21466	)	_	
103-8	21467-21470	The	_	
103-9	21471-21481	functional	_	
103-10	21482-21494	neuroanatomy	_	
103-11	21495-21497	of	_	
103-12	21498-21505	symptom	_	
103-13	21506-21516	dimensions	_	
103-14	21517-21519	in	_	
103-15	21520-21533	schizophrenia	_	
103-16	21533-21534	:	_	
103-17	21535-21536	a	_	
103-18	21537-21548	qualitative	_	
103-19	21549-21552	and	_	
103-20	21553-21565	quantitative	_	
103-21	21566-21572	review	_	
103-22	21573-21575	of	_	
103-23	21576-21577	a	_	
103-24	21578-21588	persistent	_	
103-25	21589-21597	question	_	
